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Abstract 
 
 
Our ability to control malaria has been challenged by increasing antimalarial 
resistance. Plasmodium falciparum undergoes dormancy in the blood stages which is 
hypothesized to be a means by which they are able to survive under drug pressure. This 
helps select for resistant parasites which grow following removal of drug. The 
mechanisms behind dormancy and the subsequent recrudescence are not fully 
understood but translating knowledge from related organisms which undergo a similar 
phenomenon might shed some light. Higher plants utilize dormancy during the early 
development stages to survive under unfavorable conditions, increasing fitness of the 
seedling and ensuring viability when this is released and it develops into a mature plant. 
Abscisic acid (ABA) and gibberellic acid (GA) antagonistically regulate this in response to 
environmental cues. We have found that both can be supplemented to 
dihydroartemesinin-induced dormant parasites to stimulate early recovery. Fluridone, an 
ABA inhibitor that releases dormancy in plants, was found to prolong it and cause a delay 
in recrudescence. These effects were observed in artemisinin sensitive and resistant 
strains.  
The apicoplast is required for recovery and supplementation of essential 
isoprenoid, isopentyl pyrophosphate (IPP), in apicoplast deficient parasites is sufficient 
enough to compensate for the lack of the organelle in antibiotic treated parasites. IPP 
plays an important role in development and metabolism of blood stage parasites as a key 
ix 
 
component of numerous secondary metabolites and protein activity by prenylation of 
isoprenoids. Its role in dormancy has not been explored prior to this study. 
Carotenoids are long-chained ABA precursors consisting of two molecules of 
geranylgeranyl pyrophosphate (GGPP). Several carotenoids as well as enzymes in that 
pathway have been identified in the blood stages of P. falciparum. The Apicomplexan 
parasite, Toxoplasma gondii synthesizes ABA, where it plays a role in signaling and 
development.  To date ABA has not been detected in P. falciparum due to limitations in 
methods previously utilized. We have found that parasites with fosmidomycin inhibition of 
isoprenoids can be rescued with GGPP supplementation which we planned to use to 
further elucidate the carotenoid biosynthetic pathway. 
We hypothesized that Plasmodium has retained the ability to biosynthesize ABA 
and aimed to confirm this. We developed a novel method to label GGPP with 13C on three 
of its isoprene units. This would be used to metabolically label isoprenoid inhibited P. 
falciparum for incorporation through the carotenoid pathway for detection of 13C-ABA.
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Chapter 1 
Introduction 
Malaria: Overview  
Malaria is a parasitic disease thought to be considered the most important one to 
man. The disease is caused by the obligate intracellular protozoa of the genus 
Plasmodium, belonging to the phylum Apicomplexa. Malaria parasites infect a variety of 
vertebrate intermediate hosts including mammals, birds and reptiles [1]. Six species are 
known to cause disease in humans: Plasmodium falciparum, P. vivax, P. ovale, P. 
malariae, P. knowelsi and more recently, P. cynomolgi [2, 3]. The latter is an emerging 
zoonotic species that transmits the disease between man and macaque monkey [4]. P. 
falciparum is responsible for the most severe form, contributing to most morbidity and 
worldwide mortality associated with the disease. Other single-celled eukaryotes in the 
phylum Apicomplexa include Toxoplasma, Cryptosporidium, Gregarinia and Babesia [5]. 
These organisms share an apical polar ring, apical complex and most but not all have an 
apicoplast. The apical complex is a defining feature that includes a series of microtubules, 
rhoptries and micronemes near the anterior end of the cell and is involved in host cell 
invasion [6, 7]. 
 
History 
Historical records of malaria infections date back to Chinese documents from 
around 2700 BC and evidence exists in other geographical texts and art over several 
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millennia [8]. The name derives from the Italian term “mal’aria” which translates to “bad 
air” due to the misconception that the disease originated from swamp fumes [9]. The 
modern discovery and identification of malaria as we know it today, began in 1880 when 
Charles Louis Alphonse Laveran, a French military doctor, identified pigmented 
unicellular parasites in blood smears as well as observed exflagellation of a gametocyte 
[10]. He named this parasite Oscillaria malariae and also noticed that the drug quinine 
eliminated it in blood. He was awarded the Nobel Prize in 1907 for his work despite initial 
skepticism from the scientific community that believed his discovery was of bacterial origin 
before it was proven to be parasitic. In 1885 Camillo Golgi, an Italian neurophysiologist, 
identified tertian and quartan malaria, which had symptomatic fevers reoccurring every 
48 and 72 hours respectively [11]. This discovery was a clue that malaria could be caused 
by different species of Plasmodium which had varying life cycles. Ronald Ross, a British 
military doctor, was key in the discovery of parasite to host transmission. In 1897, he 
discovered Plasmodium oocysts in mosquito midguts and suggested that mosquitos were 
the vector that transmitted disease to humans. He received the Nobel Prize in 1902. In 
1899, Giovanni Grassi and Amico Bignami not only demonstrated that only female 
Anopheles mosquitos transmitted malaria, but characterized the life cycles of P. vivax, P. 
malariae and P. falciparum [8]. A significant breakthrough occurred in 1976 when William 
Trager and J.B. Jensen developed a method for continuous culture of blood stage 
parasites which revolutionized malaria research [12]. Through the work done by these 
early researchers and many others, we would discover so much more about the parasite, 
disease and interactions with humans. 
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Plasmodium spp. life cycle 
Exoerythocytic stage 
The Plasmodium life cycle is complex and is differentiated into three distinct stages 
(Figure 1.1). The two asexual stages occur in the human intermediate host with the final 
sexual stage occurring in its definitive host, an Anopheles mosquito, which consists of 
about 30-40 species that transmit malaria [13]. Most P. falciparum infections are 
transmitted by A. gambiae. The exoerythrocytic stage begins when an infected female 
mosquito takes a blood meal. Sporozoites from the salivary glands are inoculated through 
the epidermis into the blood stream where they make their way through hepatic tissue. 
They pass through a Kupffer cell, specialized macrophages in the liver, and use their 
surface circumsporozoite protein (CSP) to bind and invade a hepatocyte [14]. These 
undergo several rounds of replication as they multiply and develop into hepatic schizonts. 
These grow and produce merozoites which upon rupture will enter the blood stream, 
taking anywhere from 6 to 10 days.  
 
Erythrocytic stage 
The erythrocytic stage begins when a merozoite originating from a hepatic schizont 
invades a red blood cell.  This occurs because merozoites cannot replicate outside a host 
cell. Contact with a red blood cell is initiated by merozoite surface proteins (MSP), apical 
membrane antigen-1 and erythrocyte binding antigen-175 which bind to surface receptors 
on the red blood cell [15-17]. This process will allow the apical end of the merozoite to 
reorient itself allowing the secretory organelles to form a junction that allows for rapid 
entry [18]. A small form known as a ring (0-24 hours) develops and as it matures, it 
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becomes a trophozoite (24-36 hours) [19]. Most metabolic activity occurs in this stage, 
including DNA synthesis, replication and protein translation. Rapid development occurs 
marked by morphological changes and multiplication into a schizont (40-48 hours), 
bearing 16-32 merozoites that will rupture and invade new erythrocytes to perpetuate this 
cycle. This cycle lasts about 44-48 hours in most strains of P. falciparum, P. vivax and P. 
ovale. The cycle of P. malariae is 72 hours and 24 hours for P. knowlesi [3].  
 
Sporogonic cycle 
Some blood stage parasites may differentiate into the sexual forms: male 
microgametocytes or female macrogametocytes. These have five stages of development 
marked by  morphological changes resembling trophozoites in stage I to a sickle or 
banana shape forms by stage V [20]. These are ingested by a feeding female mosquito 
taking a blood meal. Within its midgut, these will differentiate into gametes. Male 
microgametes will exflagellate and fertilize female macrogametes to form a zygote [21]. 
This stage is diploid where sexual recombination of genetic material occurs. The zygote 
will mature into an ookinete which penetrates the midgut and becomes an oocyst. This 
stage houses the sporozoites that are found in mosquito salivary glands which will go on 
to infect new hosts. This entire process can take up to 12 days.  
 
Plasmodium genome 
The Plasmodium nuclear genome was annotated in 2002 using reference strain 
3D7, which was cloned from NF54, an isolate from obtained from a Netherlands airport 
[22]. This genome is 22.9 mega bases (Mb) with 14 chromosomes, 5269 genes and about 
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80 gaps. It is unique in that it is primarily adenine+thymine (A+T) rich (~ 80.6%). Parasites 
contain two additional genomes. The apicoplast organelle contains a 35 kilobase (kb) 
circular genome and the mitochondrion contains a 6 kb linear genome, that encodes three 
protein genes and large and small subunit ribosomal RNA genes [23].  
 
Symptoms and diagnosis 
Uncomplicated malaria 
Uncomplicated malaria occurs in patients that are symptomatic but show no signs 
of severity or vital organ dysfunction [24]. Symptoms may include febrile illness, 
headache, dizziness, abdominal pain, vomiting, nausea and loss of appetite. A paroxysm 
cycle of relapsing chills and fever is characteristic of the disease. These are synchronized 
to the life cycle of parasites in the asexual blood stages, which contribute to most 
observed symptoms [25]. Rupture of red blood cells infected with schizonts leads to a 
release of toxins and hemazoin that stimulate host immune system to secrete pro-
inflammatory cytokines that elicit an inflammatory response. Anemia may develop as a 
result to the loss of red blood cells. P. falciparum is responsible for malignant tertian 
malaria, whereas P. vivax and P. ovale are responsible for benign tertian malaria. These 
describe the cycle of fevers that occur every third day. P. malariae causes benign quartran 
malaria and the cycles occur every fourth day. 
 
Severe malaria 
Severe malaria is primarily caused by P. falciparum infections and is more fatal 
with a high mortality [26]. This is hypothesized to be due to rapid growth of parasites and 
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cytoadherence which leads to blockage in the microvasculatures [27]. This result in vital 
organ failure, including pulmonary edema and acute renal failure, cerebral malaria, 
severe anemia, hyperparasitemia, jaundice as well as acidosis and hypoglycemia [28]. 
These become serious problems as they can develop fairly quickly within hours and death 
within a few days without prompt and proper treatment. Cerebral malaria patients 
experience coma after hypoglycemia and/or seizures [29]. Infected red blood cells 
sequester in brain microvasculatures and cause endothelial damage [30]. This can cause 
blockage which deprives the brain of oxygen (cerebral hypoxia). Placental malaria in 
during pregnancy involves parasites adhering to placenta putting both mother and unborn 
child at severe risk [31]. Less common is severe malaria from P. vivax which has resulted 
in fatal cases attributed to increasing resistance in Papua, Indonesia [32] 
 
Diagnosis 
Diagnosis for malaria is not always straightforward as several of the typical 
symptoms are non-specific to malaria and are common to other diseases. This overlap 
can lead to delays in diagnosis which impacts prompt treatment resulting in death in many 
regions. Some factors that may complicate or influence the efficacy and identification of 
malaria include sequestering of infected red blood cells, different forms of the 
Plasmodium spp., and recurrent infections [33]. Diagnostic tests and techniques exist to 
confirm malaria infection with microscopy and malaria rapid diagnostic tests (RDT) 
recommended by the World Health Organization (WHO). Giemsa staining of thick and 
thin blood smears allows for identification of parasite life stage, quantification of 
parasitemia as well as differentiating between Plasmodium species. RDTs look for 
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antigens expressed by parasites in infected blood and may detect and distinguish 
between multiple species [24]. RDTs tend to be quick and cost efficient and do not require 
lab equipment and electricity. Immunofluorescence antibody testing exists which detect 
species-specific antigens [34]. These can be time consuming and limits their practical use 
in most cases of acute malaria due to the time needed for antibody development, which 
may take up to two weeks. They are however very sensitive and specific [33]. More recent 
molecular developments have paved the way for newer diagnostic methods with high 
sensitivity and specificity. PCR-based diagnostic tests are sensitive enough to pick out 
infections with low parasitemia as well as detect drug resistant strains [33]. PCR testing 
is limited due to its high cost, trained technicians capable of running the test and complex 
methods. Other techniques include mass spectrophotometry and microarrays, which are 
not routinely used due to required resources and high cost in additional to equipment and 
quality control not practical for regions of some endemic developing countries [33]. 
 
Global health impact 
Risk of malaria is widespread as it continues to be a significant parasitic disease 
across the world with half the world’s population (over 3 billion people) estimated to be at 
risk of being infected [35]. The most recent WHO Malaria World Report reported that there 
were 214 million cases of malaria in 2015 with 438,000 global deaths [36]. It is primarily 
found in countries with warm temperate climate due to optimal growth conditions for the 
mosquito vector. Developing countries with limited access to antimalarials and poor 
control programs tend to be most affected. P. falciparum is primarily endemic to Africa 
where most fatalities occur and has a lower prevalence in other continents.  The majority 
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of these deaths occur in young children under the age of 5 that are particularly vulnerable. 
Pregnant women also are at high risk for infection [31]. 
P. vivax has a larger worldwide distribution as it is endemic in most malaria inflicted 
countries, especially those in South America, Oceania, Asia and Horn of Africa [37]. 
Several factors can explain why P. vivax is more prevalent. While very similar, P. vivax 
and P. falciparum have different biology that effects transmission as well as treatment. P. 
vivax is not as widespread in Africa due to decreased presence of the Duffy binding 
protein in the human population. Merozoites of this species require interaction with Duffy 
blood group antigens, found on the surface of young erythrocytes, for invasion [38]. 
Diagnosis can be difficult in asymptomatic patients due to low parasitemia. Methods of 
malaria control such as antimalarials and insecticide-treated bed nets which may have 
high efficacy against P. falciparum, are not as successful with P. vivax [39]. 
 
Malaria control and preventative measures 
Malaria is a disease that is preventable, treatable and curable. Prevention and 
control is achieved through a combination of vector control, protective measures and 
antimalarial treatment. Different regions will implement different policies based on local 
transmission level, financial burden and social conditions [40]. Insecticide-treated bed 
nets offer a high level of protection while sleeping by preventing mosquito to human 
interaction by repelling and killing them. Indoor spraying of insecticides in residential 
areas can also lead to lower transmission. Together any combination of these 
interventions may help reduce the incidence of malaria infection. However this has been 
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hampered due to insecticide resistance, antimalarial resistance and financial costs of 
control programs. 
A global effort to eradicate malaria came in 1955 with the Global Malaria 
Eradication Program [41]. Vector control in the form of DDT was used as an insecticide 
that targeted adult mosquitos and helped in eliminating malaria in Europe and North 
America. It however failed in many countries and was eventually abandoned by 1969. 
Currently, the WHO Global Malaria Program aims to control and eliminate malaria by 
2030 by reducing malaria case incidence and mortality rates by 90% and eliminating the 
disease in at least 35 countries [36].  
 
Vaccines 
Vaccines have historically been instrumental in accelerating eradication of many 
diseases that were once endemic to the world. An effective vaccine would be ideal to 
helping eliminating malaria; however there is currently no commercially available vaccine 
for the disease due to the complexity of the life cycle and  its genetic diversity [42]. 
Potential vaccine candidates aim at targeting key points in the parasite life cycle that could 
disrupt transmission and/or kill the parasite. Pre-erythrocytic vaccines (PEV) aim to 
reduce the likelihood of becoming infected. These target the liver stages and aim to 
prevent sporozoites from developing into blood stage infections. The most advanced 
candidate is RTS,S/AS01, recently completed Phase III clinical trials [43]. It was able to 
help protect young children for at least three years after vaccination but efficacy wanes 
over time [44]. Blood-stage vaccines (BSV) aim to block infection in the blood stages 
where most pathogenesis originates. Leading BSV candidates involve merozoite proteins 
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involved in attachment and invasion of erythrocytes [45]. The first malaria vaccine 
candidate, SPf66, was comprised of sequences of peptides from merozoite and CSP 
proteins. It was abandoned due to low efficacy in phase III trials [46]. Finally transmission-
blocking vaccines (TBV) do not help an infected person but block transmission of the 
parasite to the feeding mosquitos that go on to spread disease to an uninfected person 
[47]. 
 
Antimalarial Drugs and Resistance 
Antimalarials have been effective agents used to combat malaria with proper 
diagnosis and treatment. Some drugs are used as prophylactics to prevent infection while 
others are used for treatment to eliminate infection. In either case, drug resistance has 
been an obstacle that challenges effectiveness of malaria control and longevity of drug 
use. Resistance to conventional drugs such as chloroquine and sulfadoxine/ 
pyrimethamine (SP) in malaria endemic regions has rendered them ineffective in those 
areas and is a concern for other antimalarials. Parasites are well adapted to develop 
resistance and several mechanisms have been identified, including point mutations in key 
genes. Monotherapy has typically resulted in selecting for resistant parasites so 
combination therapies with complementary drugs is considered the recommended form 
of treatment.  
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Quinolines 
Quinine 
Quinine, extracted from the bark of cinchona trees, was the first drug discovered 
to treat malaria back in the 1600s. It was the predominant antimalarial used until the 
1920s when more effective drugs were synthesized [48]. Quinine is very effective against 
schizonts in P. falciparum with additional activity against gametocytes in P. vivax and P. 
malariae. WHO recommends quinine paired with the doxycycline or clindamycin for 
second-line treatment of uncomplicated malaria [24]. Unlike many other drugs, quinine 
resistance has been slow. Limited resistance tends to involve decreased sensitivity as 
reported in South America and Asia [49, 50] 
 
Chloroquine 
Chloroquine (CQ) is a 4-aminoquinoline derivative of quinine that became one of 
the most widely used antimalarial drug after towards the end of World War II in 1945. 
Digestion of hemoglobin by blood stage parasites produces heme, a toxic by-product in 
the digestive food vacuole. Normally this is detoxified by parasite enzymes but it is highly 
theorized that CQ interferes with this process when it accumulates in the vacuole. The 
quinolones had effectively controlled malaria until emergence of resistant parasites had 
spread by the late 1960s [51]. CQ resistance was identified along the Thailand-Cambodia 
border in Southeast Asia and Panama-Colombia border in South America in the late 
1950s. This migrated to nearby countries and was widespread throughout Africa by the 
1980s. One potential reason for this was the introduction of CQ into table salt which may 
have accelerated the rate of resistance formation [52]. 
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CQ resistance has been identified in parasites with mutations in the pfmdr1 
(Plasmodium falciparum multidrug resistance gene 1) gene and the pfcrt gene that 
encodes the Plasmodium falciparum chloroquine resistant transporter (PfCRT) protein 
[53, 54]. This protein is localized in the food vacuole and a Lys-to-Thr amino acid 
substitution at residue 76 (K76T) results in CQ resistance. This mutation causes the 
protein to shuttle CQ out of the vacuole where it is active. CQ is used as a prophylaxis 
and for treatment of P. vivax, which resistant strains have only been reported in Indonesia 
and Papua New Guinea [55, 56]. 
 
8-aminoquinolines:  Primaquine and tafenoquine 
Primaquine is the only FDA licensed drug that kills dormant P. vivax hypnozoites 
in the liver. It is an 8-aminoquinoline that has strong gametocytocidal activity against 
stage V P. falciparum gameotcytes that is effective at blocking transmission. Primaquine 
metabolism is not fully understood but it is strongly believed to be linked to cytochrome 
P450 2D6 (CYP2D6) activity which metabolizes it [57]. Those metabolites generate 
reactive oxygen species by oxidizing hemoglobin [58]. Glucose-6-phosphate 
dehydrogenase (G6PD) deficiency limits the use of primaquine in areas where this is 
prevalent due to resulting severe hemolytic anemia in patients. Resistance to the drug is 
defined as a failure to clear liver stage parasites since it is not used as a schizonticidal 
drug in the blood stages [42]. Due to primaquine’s short half-life that requires daily 
treatment, leading to poor compliance and evidence of resistance, tafenoquine, another 
8-aminoquinoline, was created as an alternative antimalarial for radical cure of P. vivax 
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malaria [59]. Its mechanism of action is not known but it has been shown to be more 
effective than primaquine [60]. 
 
Piperaquine 
Piperaquine was first used as prophylaxis and treatment of malaria after it was 
synthesized in the 1960s but this declined following emergence of P. falciparum resistant 
strains and development of more effective drugs in the 1980s [61]. It was reintroduced in 
the 1990s as a partner drug to dihydroartemesinin (DHA) due to effective clinical efficacy 
and little toxicity. Resistance has been associated with copy number variation on 
chromosome 5 (X5r) and pfcrt [62]. A recent study has reported piperaquine-DHA 
resistance in Cambodia which has been attributed to failure in both drugs to effectively 
clear infection [63] 
 
Mefloquine 
Mefloquine was introduced as an antimalarial after resistance to chloroquine and 
pyrimethamine spread. It has been available since the mid-80s and is effective at 
preventing malaria caused by chloroquine-resistant P. falciparum (CRPF) [64]. It is a 
quinolone methanol that localizes and accumulates in the food vacuole where it is believe 
to interfere with hemoglobin digestion. It is effective against blood stage parasites but has 
no activity against liver stages. Resistance developed within 6 years along the borders of 
Thailand [65]. Increased copy number of pfdmr1 is a marker for in vivo and in vitro 
mefloquine resistance. Increased susceptibility is conferred by single nucleotide 
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polymorphisms in vitro, however this is not the case in vivo [65]. It is often paired with 
artesunate due to its strong activity and long half-life [66]. 
 
Antifolates 
Antifolate drugs were first discovered in the 1940s and have been used as 
prophylaxis and treatment of malaria. These inhibit the pathway for folate metabolism in 
Plasmodium which is essential for growth. Folate cofactors provide purines and 
pyrimidines for DNA replication and are required for amino acid synthesis and catabolism 
[67]. The enzyme dihydropteroate synthase (DHPS) constructs dihydropteroate from p-
aminobenzoic acid (pABA) and L-glutamate moieties. Dihydrofolate reductase (DHFR) 
then converts dihydrofolate into its reduced form, tetrahydrofolate [67]. Plasmodium can 
either synthesize folate de novo or salvage it from host plasma. Antifolate antimalarial 
drugs fall into two classes; DHPS inhibitors (class I) and DHFR inhibitors (class II). These 
act to decrease methionine synthesis and lower thymidylate levels, arresting DNA 
replication in the process [68]. They are especially effective on late trophozoites when 
DNA synthesis is high [68]. 
The primary DHFR inhibitors that have made it to at least Phase I trials in humans 
include proguanil, cycloguanil, chlorproguanil, pyrimethamine and WR99210, the most 
potent one [69]. These have higher binding affinity for Plasmodium DHFR over human, 
making them strong drug candidates. They have slower activity against blood stage 
parasites compared to quinine but are used as a prophylaxis or in combination with faster 
acting drugs. Pyrimethamine is often administered in combination with sulfalene or 
sulfadoxine due to strong synergistic effects. DHPS inhibitors interfere with parasite de 
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novo synthesis of folate [69]. Dapsone (a sulfone) and sulfadoxine represent DHPS 
inhibitors. Alone, they tend to be toxic and have low efficacy but have considerable 
synergy with DHFR inhibitors. Sulfadoxine/pyrimethamine (SP) are often administered 
together and have replaced chloroquine in areas where resistance has been reported 
[68]. In vitro pyrimethamine resistance is attributed to point mutations in the dhfr domain 
of the dhfr-ts gene [70]. SP resistance has developed and is associated with treatment 
failure across Africa, Asia and South America [71]. It is ineffective in many of these areas 
but is used in combination with Artemisinin-based combination therapies (ACT) [24]. 
 
Atovaquone 
Atovaquone is a naphthoquinone that is administered in combination with 
proquanil as Malarone™ for treatment of uncomplicated malaria and prophylactically to 
travelers of malaria endemic countries [72]. Atovaquone inhibits the Qo site of the bc1 
complex of the mitochondrial electron transport chain (ETC) to disrupt activity of the 
mitochondrion [73]. This has direct effects on pyrimidine biosynthesis as the 
mitochondrion provides orotate for it via dihyrdoorotate dehydrogenase (DHODH). 
Resistance is associated with a point mutation at position 268 on cytochrome b resulting 
in strains that become far less susceptible to Malarone™ treatment [74, 75]. 
 
Antibiotics 
Several antibiotics used to treat bacterial infections are effective against 
Plasmodium, unsurprisingly due to shared biology acquired through the apicoplast, a 
plastid-like organelle with cyanobacterial origins [76]. Activity tends to be slow but some 
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classes nonetheless are used as antimalarial prophylaxis or in combination with faster 
acting drugs. 
Most antibiotics exhibit what is known as a delayed death phenotype [77].  
Exposure in the first life cycle interferes with apicoplast replication so that daughter 
parasites in the second life cycle fail to inherit the organelle. Without an intact apicoplast 
present, all associated metabolism is disrupted and parasites fail to replicate and die 
within 96 hours. Morphologically parasites appear normal in the first 48 hours but 
unhealthy schizonts in the subsequent life cycle fail to produce merozoites and therefore 
are unable to complete schizogony. The delayed death effect results in a parasite 
clearance delay, which is why these are paired with fast-acting drugs. This phenotype is 
observed in parasites exposed to macrolides such as azithromycin, lincosamides such as 
clindamycin and  tetracyclines such as doxycycline [78].  
Tetracyclines are broad-spectrum protein synthesis inhibitors that bind to the 30S 
subunit of ribosomes to block aminoacyl-tRNA attachment in bacteria. They are used as 
slow-acting antimalarials that target the apicoplast. The most commonly used one is 
doxycycline, synthesized in the early 1960s. It is used prophylactically by international 
travelers to Africa, Southeast Asia and South America due to its long half-life [79]. It is 
often recommended as a partner drug to quinine or artesunate in treatment of severe 
malaria [24]. To date, no clinical resistance to doxycycline has been reported. 
 
Fosmidomycin 
Following discovery of the methylerythritol phosphate (MEP) pathway in 
Plasmodium, several drug targets were pursued. Fosmidomycin (FOS) and its derivative, 
17 
 
FR900098 were found to inhibit growth in multidrug-resistant P. falciparum strains [80]. It 
inhibits an apicoplast target that does not result in delayed death but rapidly kills parasites 
within the first life cycle. Fosmidomycin inhibits 1-deoxy-D-xylulose-5-phosphate 
reductoisomerase (DXR) a key enzyme in the isoprenoid biosynthetic pathway. Clinical 
efficacy of fosmidomycin monotherapy is limited and not ideal as patients in Thailand and 
Gabon developed highly recrudescent infections [81].  Symptoms cleared rapidly and 
microscopic detection of parasites dropped below threshold for detection but parasites 
were not fully cleared. Fosmidomycin has been tested clinically in combination with 
clindamycin or artesunate. Both combinations resulted in high cure rates but adverse 
effects such as neutropenia and vomiting were of concern [82, 83]. 
 
Artemisinin 
Artemisinin is derived from the Chinese herb, qinghao of Artemisia annua L. also 
known as sweet wormwood. Evidence of its use in fever treatment, traces back to 340 
C.E [84]. Following failure of many drugs due to resistance and efforts to eradicate 
malaria, an initiative was created to look for new antimalarial compounds [51]. Activity 
against Plasmodium was first discovered in 1971 by Youyou Tu and its active ingredient 
was isolated and termed qinghaosu or artemisinin as it is currently referred to [51]. 
Artemisinin is recognized as the leading drug to treat malaria. Since 2005, ACTs are 
recommended by WHO as the gold standard of treatment. These include fast acting 
artemisinin derivatives paired with a slower acting partner drug [24].  
Among the many artemisinin derivatives include arteether (AE), artemether (AM), 
artesunate (AS), artelinic acid (AL) and dihydroartemesinin (DHA), all of which vary in 
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solubility and efficacy, but maintain strong activity against P. falciparum [85]. These 
derivatives also vary in how they are metabolized and administered. Unlike artemisinin, 
most of these derivatives metabolize to DHA in human body and inactive metabolites. 
DHA tends to be the most potent, being more stable and effective than aretemisinin [51]. 
Artemisinins are among the most potent drugs used to treat malaria with inhibitory 
concentrations (IC50) in the nanomolar range. The length of time it takes for the derivatives 
to hydrolyze to DHA tends to mediate their activity with AS taking about 10 minutes 
compared to AM’s slower conversion. 
DHA has a short half-life of about 45 minutes and its fast activity is attributed to its 
short elimination time. ACTs pair artemisinin derivatives with less potent drugs that act 
slowly as there are less parasites to clear following metabolism of the artemisinins. Most 
parasites are eliminated by artemisinins and the partner drug kills off residual parasites. 
This combination also helps reduce the risk of resistance development by decreasing the 
chance of selection of resistant parasites. The partner drugs theoretically should be able 
to eliminate parasites that may develop artemisinin resistance [86]. Common 
combinations include AM + lumefantrine, AS + amodiaquine, AS + mefloquine, AS + SP 
and DHA + piperaquine [24]. 
 
Mechanism of action 
Artemisinin’s mechanism of action is not fully understood and remains a topic of 
hot debate. Artemisinin is a sesquiterpene trioxane lactone, bearing an endoperoxide 
bridge believed to be key to its activity. One theory proposes that artemisinin is selectively 
activated by parasites through interaction with free iron which is in higher abundance in 
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infected erythrocytes due to digestion of hemoglobin. Iron cleaves the bridge and release 
free radicals that are toxic to parasites [87]. This targets nucleophilic groups of proteins 
and lipids, disrupts heme detoxification and depolarizes membrane potential [88, 89]. 
Another theory suggests it acts through inhibition of PfATP6, a sarco/endoplasmic 
reticulum membrane calcium ATP-ase (SERCA) enzyme [90].  
 
Artemisinin resistance 
Southeast Asia has been a hotbed for emergence  of multi-drug resistant P. 
falciparum parasites resistant to antimalarials including chloroquine, pyrimethamine, 
mefloquine and quinine [86]. ACT failure and resistance to artemisinin is emerging and 
alarming. Artemisinin (partial) resistance is delayed parasite clearance following therapy 
[91]. Full resistance is represented by strains that survive and multiply despite exposure 
to drug doses equal or higher than what is recommended but tolerable to the subject [24]. 
Artemisinin full resistance has not yet emerged but partial resistance may select for 
resistance in partner drugs. Point mutations in the PF3D7_1343700 kelch propeller 
domain on chromosome 13 (K13) have been identified as a molecular marker for in vitro 
and in vivo artemisinin resistance [92]. Kelch represents a superfamily of proteins that 
contains protein-protein interaction sites and is involved in a variety of cellular functions 
response to oxidative stress and protein degradation.  K13 mutations in artemisinin 
resistant parasites are less susceptible to incoming oxidative damage created by 
artemisinins [86]. A recent study reveals phosphatidylinositol-3-kinase (PfPI3K), a binding 
protein for K13, as a potential target of the drug [93]. K13 targets PfP13K for degradation 
in sensitive parasites. Binding is disrupted in resistant parasites resulting in higher basal 
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levels of PfP13K and P13-phoshphate (P13P) which enhances survivability of artemisinin 
exposed parasites [94].  
 
Dormancy 
Dormancy in Plasmodium falciparum 
Recrudescent infections are often observed when antimalarials are administered 
alone. This is seen with artemisinin derivatives where recrudesce occurs in up to 50% of 
patients that are given artemisinin monotherapy [95]. Length of treatment can reduce the 
rate of recrudescence. Recovery from malaria occurs when parasite clearance is 
observed in peripheral blood smears but this may not happen in highly resistant parasites. 
Some resistant parasites may fall below the level of microscopic detection and lead to 
recrudescence when parasitemia increases and clinical symptoms of malaria manifest 
[96].  
Dormancy as a concept has been theorized as a means by which P. falciparum 
evades drug stress and eventually recrudescence following exposure to antimalarials. In 
1996, Kyle and Webster reported a growth arrest of ring stage parasites exposed to AS 
or DHA [97]. These “dormant” parasites resumed growth after 3-8 days. Ring stage 
parasites are susceptible to stress which halts progression to the more mature trophozoite 
stage. In vitro studies reveal that a morphological change is induced transforming the ring 
into a small pyknotic like form identifiable by a condensed nuclei and cytoplasm and 
absence of the vacuole. Exposure to 700 nM DHA for 6 hours is enough to induce this 
phenotype in standard lab strains. This concentration and exposure length is 
representative of serum level of DHA that is metabolized by patients treated with 
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artemisinin derivatives. Growth commences when drug pressure is removed and the 
erythrocytic cycle is able to continue development [98, 99]. Recovery ranges from 0.044% 
to 1.313% following removal in a dose dependent manner. Recovery can also be reduced 
with additional treatments of DHA over 3 consecutive days [99].  
Dormant parasites are not completely quiescent as low levels of metabolism are 
maintained. DHA was used to induce dormancy in P. falciparum and transcriptional data 
of 12 genes encoding key enzymes in different metabolic pathways was assessed [100]. 
Most of these genes were downregulated but genes encoding pyruvate kinase 2 (pykii), 
long-chain fatty acid elongation enzyme (lcfaee) and cytochrome c oxidase subunit II 
(coxii) were maintained in the 48 hours following DHA treatment. The first two are 
apicoplast proteins and the latter is of mitochondrion origin. Further analysis of apicoplast 
genes during dormancy reveal that genes encoding enzymes used for pyruvate 
metabolism, fatty acid synthase II (FASII) and lipoyl metabolism in the apicoplast are also 
maintained. 
Assessment of mitochondrial membrane potential with rhodamine 123 (RH) 
reveals that a subset of artemisinin-induced dormant parasites RH-positive recover 
whereas RH-negative parasites do not. Transcription of mitochondrial enzymes is only 
present in RH-positive dormant parasites suggesting a critical role that mitochondria plays 
in recovery from dormancy [101]. 
Hott et al demonstrated that pyrimethamine is capable of inducing a second cycle 
ring-stage dormancy [102]. Rings of artemisinin-resistant and susceptible clones exposed 
to the drug are not immediately arrested. Instead development continues through 
schizogony and daughter rings in the subsequent life cycle are met with arrested growth. 
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Morphologically these parasites appear similar to those exposed to DHA and 
recrudescence is observed 5-11 days later. In vitro recrudescence to atovaqone, 
proguanil, mefloquine and pyrimethamine have also previously been reported in P. 
falciparum [103-105]. 
 
Dormancy in other Plasmodium spp.  
P. vivax is capable of developing into dormant forms known as hypnozoites upon 
invading hepatic cells [106]. These hypnozoites can lead to relapse infection when they 
resume growth. Relapse is also observed in P. ovale as well as the simian parasite, P. 
cynomolgi but is not present with P. falciparum infections. Latency, described as the 
period between initial infection and relapse can be anywhere from a few weeks to years 
[107]. Long-latency P. vivax infections occur when primary infection or first relapse is 
observed within months of initial mosquito bite. Short-latency infections appear more 
rapidly with relapse rates up to 90% within 6 weeks of primary infection [37]. Relapse 
infections in patients in non-endemic areas provide evidence of the presence of dormant 
parasites that reside from previous infections. Mechanisms behind hypnozoite formation 
and subsequent relapse remain unknown although there is a theory that interaction with 
Anopheles protein following a bite from uninfected vector might activate these dormant 
forms [108]. 
In vivo assessment of dormancy has been worked on using rodent models. 
Synchronous P. vinckei petteri and P. v. vinckei infected with artesunate exhibited 
dormant parasites 24 hours after treatment. Micrograph images revealed parasites that 
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looked similar to P. falciparum [109].  This demonstrates that dormancy can be induced 
in vivo and is not limited to in vitro parasite cultures. 
 
Dormancy in Plants 
Dormancy represents an important physiological mechanism in early plant 
development that promotes survival and viability. There are several classifications of 
dormancy in plants and each represents a developmental arrest that halts germination 
[110]. Germination is a natural developmental process of a viable seed into a mature 
plant. It starts with absorption of water by the seed resulting in embryo expansion. 
Germination ends when the outer seed layers rupture, revealing the radicle, the growing 
plant embryo. The definition varies but generally seed dormancy represents a mechanism 
that prevents a  viable seed from germinating [111]. Primary dormancy describes 
germination arrest in mature seeds; the seed is released from a plant already dormant. 
This differs from secondary dormancy which describes mature seeds that undergo 
dormancy following environmental cues. Seed dormancy is further subdivided into 
embryo and coat dormancy. Abscisic acid, gibberellins, ethylene, brassinosteroids, and 
auxins, cytokinins, all interplay to regulate dormancy and affect plant development [112]. 
The extent to which hormones and environmental cues dictate dormancy varies with 
species [113]. Most research has been done with Arabidopsis thaliana, a model flowering 
plant that has provided much knowledge on this phenomena, which is not fully understood 
[114]. 
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Abscisic Acid 
Abscisic acid (ABA) was originally thought to be involved in abscission,  the 
detachment of plant parts such as leaf and fruit [115]. ABA is rapidly synthesized under 
unfavorable conditions that induce stress, which include heat, salinity, chilling and 
herbicide toxicity [116]. It serves as a positive regular of dormancy and negative regulator 
of germination in many plant species.  ABA binds to pyrabactin resistance I (PYR1) 
receptors and PYR1-like (PYL) receptors which do not appear to be in other organisms 
[117, 118]. Seed development corresponds to two peaks of ABA accumulation [119]. 
Maternal ABA is first produced by parent plant is transferred to seeds. This is unable to 
induce dormancy, but it promotes embryo growth during embryo development and 
increases seed yield [120]. The embryo provides the second peak and it is this ABA that 
regulates dormancy. 
 
Gibberellic acid 
Gibberellins are diterpene phytohormones that function as growth promoters and 
affect developmental processes. They compose of a class of gibberellic acids (GA), many 
of which are nonbioactive [121]. The primary bioactive gibberellins are GA1, GA3, GA4 
and GA7. They are negative regulators of dormancy and positive regulators of germination 
that work antagonistically with ABA. GA-mediated dormancy releasing mechanisms are 
unknown but it theorized to be possibly be due to secretion of hydrolytic enzymes that 
weaken the outer seed testa [122]. 
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Dormancy and persistence in other organisms 
Persistence has been described in organisms that exhibit a phenotype 
representing dormancy. Tumor cells in cancer may go dormant following treatment. 
Tumor dormancy  is defined as a phase without cancer progression, in which a single 
tumor cell or clusters show no signs of growth but have the capacity for malignant 
progression [123]. This is responsible for relapses with a subset of cells that may survive 
following initial treatment. Dormant cells ensure proliferation and may be more drug 
resistant. Therapies not only select for cancer stem cells but rather those with resistance 
mutations that make them less susceptible to forms of therapy [124, 125].  
Some bacterial cells are able to evade antibiotic toxicity in the absence of genetic 
change [126]. These drug-tolerant bacterial persisters originally make up a small 
proportion of a population but grow exponentially and may be the cause of chronic 
infections. While not entirely dormant, these cells undergo a growth arrest followed by 
rapid expansion similar to dormancy and recrudescence that promotes survival of 
antibiotic resistant bacteria. They are less susceptible to antibiotics due to the decrease 
in cellular activity [127]. Persistence genes exist which provide genetic basis for this [128]. 
These were identified in mutant E. coli strains. The global regulators were associated with 
increased tolerance to antibiotics and overexpression contributes to dormancy. 
 
Apicoplast 
Origins 
The apicoplast is a relict plastid-like organelle common to most Apicomplexan 
parasites but is absent in Cryptosporidium spp. and some gregarines [129, 130]. The first 
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hints of this came from circular extrachromosomal DNA in Plasmodium lophurae, which 
was initially thought to be of mitochondrial origin [131]. Discovery of the linear 6kb 
mitochondrial genome disproved this and eventually it was determined that it was more 
linked to plant and algal plastids [132, 133]. The complete genome of the organelle was 
mapped in 1996 and found to highly resemble algal plastid DNA [134]. This circular 
genome consisting of 35 kb is called the plastome [76, 135]. This number is reduced down 
from 150 kb found in the average chloroplast due to highly selective pressure. It is about 
86% A/T rich and contains 68 genes that encode less than 50 proteins, most of which are 
nuclear encoded and targeted to other organelles [135-137]. 
The Apicomplexan plastid became known as the apicoplast and parasites today 
evolved to contain it through two endosymbiotic events. Initially an ancient 
cyanobacterium was engulfed by a heterotrophic eukaryote. This new red algae organism 
was then engulfed by another eukaryote and with lateral genetic transfer evolved into 
chromalveolates, which include dinoflagellates, diatoms and Apicomplexans via 
secondary endosymbiosis. Evidence of this is seen in the apicoplast’s four membranes 
and genome which is similar to that of red algae [136]. The inner membrane is the plasma 
membrane of the endosymbiont and the next two originated from the red algal plastid. 
The outer membrane originates from the host’s endomembrane [138]. Integrating the 
endosymbiont into the host cell as an organelle involved using its resources, regulating 
division and preventing it from escaping the host [138]. 
The plastid is no longer photosynthetic, having lost this ability as it is not needed 
within a host. It is however essential for survival as disruption leads to parasite death 
[139]. It is capable of four functions: heme biosynthesis, iron-sulfur cluster biosynthesis, 
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fatty acid and isoprenoid biosynthesis. Genes for fatty acid biosynthesis were identified 
in Toxoplasma gondii and P. falciparum in 1998 [140]. Shortly after a biosynthetic 
pathway for isoprenoids was linked to the apicoplast [141]. Eventually it was elucidated 
that the apicoplast produced iron-sulfur clusters and was involved in heme biosynthesis 
[142]. 
 
Fatty Acids 
Fatty acids are found in all living cells and are the building blocks of lipids, second 
messenger precursors, energy storage molecules and are used for protein 
posttranslational modification [143]. Fatty acids are synthesized by two distinct pathways. 
Type I is generally found in fungi and mammals and Type II occurs in plants and bacteria 
[144]. Type II fatty acid synthesis (FASII) pathway occurs in the apicoplast. Plasmodium 
spp contains all enzymes required for FASII pathway and nuclear FASII genes encode 
products that target the organelle [142]. Covalent attachment of acyl intermediates to acyl 
carrier protein (ACP) is a feature unique to Type II. Addition of a 4’-phosphopantetheine 
prosthetic group to the ACP is required for its participation in fatty acid biosynthesis [145]. 
ACPs transfer fatty acids between enzymes in the pathway and are localized to the 
apicoplast [146].  
A key product of FASII is lipoic acid, an essential co-factor of the glycine cleavage 
system, pyruvate dehydrogenase (PDH), α-ketoglutarate dehydrogenase (KGDH) and 
branched chain α-ketoacid dehydrogenase (BCDH). The latter three are multi-enzyme 
complexes found in the mitochondria and apicoplast that contribute to amino acid and 
energy metabolism [147]. Initially this pathway was an attractive target for blood stage 
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drug discovery. We now know that FASII is nonessential in the blood stages as mutants 
lacking this pathway remain viable, scavenging lipids from host. However deletion of key 
FASII genes revealed that the pathway is essential in the liver stage as well as sporozoite 
development in mosquito midguts [148, 149]. P. berghei lacking the LipB gene (which 
encodes octanoyl-ACP transferase) develop normally in the blood and mosquito stages, 
but this is disrupted in liver [150]. FabZ knockout in P. yoelli resulted in liver schizonts 
that fail to produce merozoites [149]. Finally deleting P. falciparum fabI and fabB/F 
resulted in midgut oocysts that did not produce sporozoites [148]. 
 
Iron-sulfur clusters 
Iron-sulfur (FeS) clusters are protein cofactors that are involved in electron 
transfer, sulfur atom donation, sensing process as well as structural roles [151]. They 
consist of Fe2+/3+ and S2- ions [143]. FeS synthesis uses two pathways; the Isc pathway 
localized in the mitochondrion and the Suf pathway found in the apicoplast, similar to 
organization in plant plastids. The Suf pathway provides FeS clusters for lipoate 
synthesis, redox and tRNA modification in the apicoplast. FeS clusters also serve as 
cofactors for enzymes (IspG and IspH) in the final steps of the MEP pathway for 
isoprenoid biosynthesis. The Suf pathway is required for apicoplast maintenance as SufC 
dominant negative mutants do not contain the organelle [152]. 
 
Heme biosynthesis 
Heme is a source of iron that can be used by FeS proteins [153]. Mammalian heme 
is synthesized in the mitochondrion and primarily in plastids for plants [143]. The pathway 
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for heme biosynthesis in Plasmodium however is a coordinated effort between the 
apicoplast, mitochondria and cytosol. Synthesis begins in the mitochondrion where the 
first and last two enzymes are localized. The rest are located in apicoplast and cytosol 
and are shuttled by parasite transporters. De novo synthesis of heme is nonessential in 
blood stages as there is an abundance of heme in host cell. It is however essential in the 
mosquito and liver stages. Knockout of δ-aminolevulinate synthase (ALAS) and 
ferrochelatase (FC), the first and last enzyme of the heme biosynthetic pathway resulted 
in P. berghei parasites with reduced oocysts that failed to produce sporozoites [154].  
 
Isoprenoids 
The primary isoprenoid is the 5 carbon isopentyl pyrophosphate (IPP) and its 
isomeric form dimethylallyl pyrophosphate (DMAPP). IPP is non-allylic and differs in the 
position of its double bond. Multiple isoprene units (IPP or DMAPP) build on each other 
to form longer isoprenoids such as the 10 carbon, geranyl pyrophosphate (GPP), 15 
carbon farnesyl pyrophosphate (FPP) and 20 carbon geranylgeranyl pyrophosphate 
(GGPP). This pathway is essential in the blood stages of Plasmodium as inhibition with 
fosmidomycin leads to death but can be recovered with exogenous IPP [155]. Treatment 
with antibiotics disrupts apicoplast development such that parasites in the second life 
cycle fail to inherit one, resulting in death. This can also be rescued with exogenous IPP 
(Figure 1.2). 
The biological significance of isoprenoids cannot be understated as they represent 
one of the largest class of metabolites found in all organisms, comprising of over 35,000 
compounds [156]. They are utilized for a variety of cellular process including 
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mitochondrial ubiquinone cofactor (coenzyme Q) biosynthesis, protein posttranslational 
modification, cell signaling, and tRNA modification [143]. Ubiquinones represent a major 
end product of isoprenoid biosynthesis that play an essential role in mitochondrial electron 
transport. Most surface proteins depend on dolichol transfer of 
glycosylphosphatidylinositol (GPI) anchors to bind to membranes. Isoprenoids are also 
required for protein prenylation which involves the attachment of either farnesyl or 
geranylgeranyl to proteins. Additionally isoprene units are components of the long 
chained carotenoids. 
 
Carotenoids 
Carotenoids are pigments produced by photosynthetic plants as well as some non-
photosynthetic bacteria and fungi [157]. These 40 carbon molecules share GGPP as a 
precursor and are synthesized in plastids. They are known for their chemical and physical 
properties used in scavenging freed radicals, light absorption and antioxidant activity. 
Evidence of carotenoid biosynthesis was discovered in P. falciparum in 2009, utilizing [1-
3H] GGPP as a metabolic precursor to follow the pathway [158]. Phytoene, β-carotene 
and lutein were all identified and characterized through high performance liquid 
chromatography (HPLC) and mass spectroscopy. Norflurazon, an inhibitor of phytoene 
desaturase, depleted downstream products while increasing phytoene levels. Additionally 
an enzyme (PfB0130w) with phytoene synthase activity was identified. This catalyzes the 
reaction that converts two molecules of GGPP into phytoene.  
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Isoprenoid Biosynthesis 
IPP is synthesized via two mechanisms in nature that vary in precursors and cell 
localization (Figure 1.3). Most eukaryotes, including humans and plants, fungi, 
archaebacteria and a few eubacteria utilize the classical mevalonate (MVA) pathway 
[156]. This is also known as 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) pathway and 
occurs in the cytosol. It begins with condensation of two molecules of acetyl-COA to 
produce acetoacetyl-CoA. HMG-COA synthase converts this to produce HMG-CoA and 
HMG reductase catalyzes the reaction to yield mevalonate. The next few steps differ 
between eukaryotic and archaea organisms but the end result is one molecule of IPP. 
Isoprenoid production is in high abundance in human hepatocytes using the MVA 
pathway, but absent in erythrocytes [159]. 
It was originally thought that isoprenoids were only synthesized via the MVA 
pathway but we now know it can occur in other organisms under a different system. Most 
eubacteria, and plastid bearing organisms, such as Apicomplexans and plants, use the 
2C-methyl-D-erythritol-4-phosphate (MEP) pathway [160]. This is also known as the 1-
deoxy-D-xylulose-5-phosphate (DOXP) or non-mevalonate pathway for isoprenoid 
biosynthesis. Biosynthesis of isoprenoids via the MEP pathway is localized in the plastid 
and eight reactions catalyzed by nine enzymes eventually yield IPP (Figure 1.3) [156]. 
Condensation of pyruvate and glyceraldehyde 3-phosphate (G3P) produces DOXP in the 
first step catalyzed by DOXP synthase (DXS). The second step involves conversion of 
DOXP to MEP by DXR. It is this process that is inhibited by fosmidomycin and grants it 
its antimalarial activity. MEP cytidylyltransferase (IspD) then releases the pyrophosphate 
from MEP in a reaction with CTP to produce 4-diphosphocytidyl-2-C-methylerythritol 
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(CDP-ME) in the third step. CDP-ME kinase (IspE) uses ATP to phosphorylate CDP-ME 
into CDP-MEP and ADP. MEcPP synthase (IspF) catalyzes the reaction that converts this 
into MECP. IspG and HMB-PP reductase (IspH) both contain iron-sulfur clusters and 
catalyze the reactions for steps 6 and 7. IspG converts MECP into 2-methyl-2-(E)-butenyl 
diphosphate and IspH converts it into IPP. IPP isomerase (IspI) will isomerize the double 
bond to form DMAPP. All enzymes are nuclear encoded and transported to the 
apicoplast. 
Evidence of isoprenoid biosynthesis in Plasmodium was reported prior to the 
discovery of the MEP pathway. Ubiquinone-8 and ubiquinone-9 were both found in blood 
of duck and monkeys infected with P. lophurae and P. knowlesi respectively in the late 
1960s [161]. It would take three decades for the pathway to be confirmed as a metabolic 
pathway in Apicomplexans [80]. The fact that it is not present in humans has made it an 
attractive target for drug discovery [80, 162]. 
 
Abscisic acid in living organisms 
Toxoplasma gondii 
ABA was discovered to be produced by T. gondii which uses it for communication. 
Nagamune et al. established that the plant hormone induces production of cyclic ADP 
ribose (cADPR), a secondary messenger that stimulates calcium release [163]. ABA 
supplementation promotes microneme protein 2 (MIC2) secretion in a dose dependent 
manner as a result of increased calcium levels. Micronemes are required for cell invasion 
and parasite motility. ABA is also mediates egress. ABA was not only detected and 
quantified in parasites extracts through gas chromatography mass spectroscopy and 
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ELISA, but was reduced in parasites exposed to 50 µM fluridone, an inhibitor of ABA with 
antagonist roles in plants. FLD also prevents egress and promotes formation of 
bradyozoites, the dormant cyst forms. 
 
Humans 
Human granulocytes produce ABA, which also stimulates calcium release via 
cADPR [164]. Granulocytes are white blood cells of the immune system that respond to 
external stimuli that cause inflammation or infection. They mediate phagocytosis of 
foreign pathogens by producing reactive oxygen species (ROS) and nitric oxide (NO). 
Supplementation with external ABA was shown to stimulate this. ABA also increases 
insulin secretion from pancreatic islets and is stimulated by glucose concentrations [165]. 
 
Plants 
ABA has expanded roles in plant organisms beyond dormancy regulation. It also 
involved in calcium signaling by inducing intracellular calcium release via cADPR. This 
occurs through its activation of ADP-ribosyl cyclase via a protein kinase A mediated 
phosphorylation [166]. ABA has also been shown to be involved in oxidative stress 
response. Levels of it can cause an increase in active oxygen species which in turn 
induces expression of antioxidant genes and enhances activities of associated enzymes 
such as superoxide dismutase, catalase, glutathione reductase [167]. ABA treatment to 
A. annua plants also increases artemisinin content by increasing expression of genes in 
the artemisinin biosynthetic pathway in a dose dependent manner [168]. Artemisinin was 
found to be 65% higher in plants exposed to 10 µM compared to controls. Gene analysis 
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shows a significant increase in expression of 3-hydroxy-3-methylglutaryl coenzyme A 
reductase (HMGR), farnesyl pyrophosphate synthase (FPS), amorpha-4,11-diene 
synthase (ADS), amorpha-4,11- diene C-12 oxidase (CYP71AV1) and cytochrome P450 
reductase gene (CPR), all of which are genes involved in biosynthesis of artemisinin. As 
a stress hormone it also mediates stromatal closure during drought and it has also been 
shown to alter mRNA translation to regulate gene expression [169, 170]. 
 
Other organisms 
ABA synthesis in some other organisms differs from the pathway found in plants. 
Fungi utilize the mevalonate pathway to make IPP and as such the precursors in ABA 
biosynthesis are not the same. ABA is created directly from farnesyl pyrophosphate (FPP) 
that bypasses the long chained carotenoids [171]. ABA is also found in cyanobacteria 
and production is increased under conditions that induce salt stress [172] ABA role as a 
global mediator of Ca2+ release is conserved across several species. It is found in the 
sponge species, Axinella polypoides [173]. Heat stress, similar to drought stress in plants, 
results in increased levels of ABA which in turn stimulated cyclase activity. ABA is 
involved in a signaling cascade in the hydroid, Eudendrium racemosum [174]. 
Endogenous ABA stimulates cADPR activity resulting in an increase of Ca2+ during light 
mediated regeneration and could be inhibited with fluridone. Exogenous ABA is able to 
stimulate cyclase activity during the dark. Exogenous ABA also enhances growth of green 
alga, Chlamydomonas reinhardtii, as well as induces tolerance to oxidative stress through 
enhancement of antioxidant enzyme activity [175]. 
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Scope of study  
Malaria, the infectious disease caused by Plasmodium spp. remains a major 
problem worldwide due in part to challenges faced such as increasing drug resistance 
and parasite recrudescence following treatment. This may be partially explained by 
dormancy, a mechanism that allows the parasite to escape stress such as that induced 
by current antimalarial treatments. Drug-induced dormancy involves the parasite entering 
a state of low metabolic activity, where infection may appear to have been cleared, but 
recrudescence occurs when parasites resume normal growth. Currently, the molecular 
basis for how the parasite is able to regulate dormancy and recrudescence is not well 
understood. We believe that ABA, a carotenoid catabolite with a well-established role in 
seed dormancy in plants, may answer some of these questions.  
Isoprenoid synthesis in Plasmodium requires the apicoplast, an organelle that was 
originally obtained via a secondary endosymbiotic relationship with red algae. The 
primary isoprenoid is IPP, which is essential for a number of metabolic processes and 
serves as the precursor for carotenoid biosynthesis and its catabolite, ABA. In this study, 
we discovered the presence of ABA in the erythrocytic stages of P. falciparum using gas 
chromatography mass spectroscopy to detect and quantify ABA levels in methylated 
parasitic extracts exposed to fluridone, a carotenoid inhibitor of ABA, and apicoplast-
targeting antibiotics.  Our preliminary data detected ABA and found it to be significantly 
decreased when exposed to these drugs. Following in vitro induction of dormancy with 
DHA, parasites were observed to resume growth earlier when supplemented with ABA 
and GA.  We also found that FLD can extend the length of dormancy and cause a delay 
in recrudescence. 
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We hypothesize that exposure to the phytohormones, ABA and GA, would 
stimulate recrudescence in DHA-induced dormancy in erythrocyte stages. We also 
believe that P. falciparum can biosynthesize ABA de novo. In this study, we aimed to 
characterize the biosynthetic pathway of ABA using an innovative approach with 13C 
labeled precursors to follow incorporation into ABA and intermediates. We also aimed to 
elucidate the role that ABA and GA have in drug induced dormancy using 
dihydroartemesinin. Our research strategy, which involved taking a novel approach by 
utilizing the evolutionary link between plants and parasites should help us broaden our 
understanding of parasite drug evasion and have an impact on development of 
antimalarials. 
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Figure 1.1: Plasmodium Life Cycle. The Plasmodium life cycle begins when a feeding 
female mosquito takes a blood meal and injects sporozoites from the salivary gland 
through the skin where they pass through the blood stream and eventually reside in a 
liver cell. During the exo-erothryocytic cycle, replication occurs and a hepatic schizont 
develops with merozoites that will be released into the blood following rupture. The 
erythtocytic cycle commences when a merozoites invades a red blood cell to form a ring 
which matures into a trophozoite, followed by a schizont which releases merozoites when 
the infected red blood cell bursts. The cycle is continued when a new invasion has  
occurred. A subset of rings may develop into sexual male and female gameotcytes which 
are ingested by feeding mosquitos. Within a mosquito midgut, male microgametes will 
exglagellate and fertilize female macrogametes, forming ookinetes which develop into 
oocysts. These release sporozoites upon rupture which make their way to the salivary 
glands, ready to infect a new person. 
 
© CDC; http://www.cdc.gov/dpdx/Malaria/ 
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Figure 1.2: Evolutionary dependence of IPP. Following a primary endosymbiotic event 
with a cyanobacterium and ancient protist, a secondary endosymbiotic event occurred 
when red algae was engulfed by a protist host. Mevalonate synthesis of IPP was 
redundant and therefore lost, leaving IPP synthesis via the DOXP pathway retained in the 
nonphotsynthetic apicoplast. IPP is shuttled outside the plastid to other parts of the 
parasite that use it. FOS inhibits the pathway by targeting DXR in the plastid. Antibiotics 
interfere with apicoplast replication, resulting a delayed death that can be chemically 
rescued with exogenous IPP. 
 
© Nair SC, Striepen B (2011) What Do Human Parasites Do with a Chloroplast 
Anyway? PLoS Biol 9(8): e1001137. doi:10.1371/journal.pbio.1001137 
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Abbreviation Definition Abbreviation Definition 
CDP-ME 4-diphosphocytidyl-2-C-
methylerythritol 
IspE CDP-ME kinase 
CDP-MEP CDP-ME phosphate IspF MecPP synthase 
DMAPP dimethylallyl pyrophosphate IspG = HMB-PP synthase 
DOXP 1-Deoxy-D-xylulose 5-phosphate IspH HMB-PP reductase 
DXR DOXP reductoisomerase IspI IPP isomerase 
DXS DOXP synthase ME-cPP methylerythritol 
cyclodiphosphate 
G3P glyceraldehyde 3-phosphate MEP methylerythritol phosphate 
HMBPP (E)-4-Hydroxy-3-methyl-but-2-enyl 
pyrophosphate 
MVA mevalonate 
HMG-CoA 3-hydroxy-3-methy-glutaryl-CoA MVP mevalonate-5-phosphate 
IPP isopentyl pyrophosphate MVPP mevalonate pyrophosphate 
IspD MEP cytidyltransferase   
 
Figure 1.3. Isoprenoid biosynthesis. Isoprenoid biosynthesis can occur via the 
mevalonate (MVA) or methylerithritol (MEP) pathway. Cell localization, precursors and 
enzymes differ. Plasmodium contains only the MEP pathway and it is localized in the 
apicoplast. It begins with a molecule of glyceraldehyde 3-phosphate (G3P) and pyruvate 
to produce IPP and DMAPP.  
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Chapter 2 
 
Phytohormones stimulate early recovery in Plasmodium falciparum dormancy 
 
Abstract 
Several organisms undergo dormancy as a stress response to survive under 
unfavorable conditions that might impede development. This is observed in seed and 
buds of plants and has been proposed as mechanism of drug evasion and resistance 
formation in Plasmodium falciparum. We explored the effects of the phytohormones, 
abscisic acid and gibberellic acid, on dihydroartemesinin induced dormant P. falciparum 
parasites in the erythrocytic stages. Parasites were phenotypically observed to emerge 
from dormancy earlier when exposed to these hormones and this could be delayed in the 
presence of fluridone, a carotenoid inhibitor. Additionally the role of the apicoplast was 
assessed in dormant parasites. These parasites remain viable for up to 8 days without 
the organelle and only recrudesce if supplemented with the isoprenoid, isopentyl 
pyrophosphate (IPP). Isoprenoid inhibition with fosmidomycin did not prevent dormancy 
release from occurring in parasites with an intact apicoplast, but IPP and geranylgeranyl 
pyrophosphate (GGPP) are needed for complete recrudescence. 
 
Introduction 
About 214 million cases of malaria and 438,000 deaths were reported in the past 
year [36]. Plasmodium falciparum is responsible for the most deadly form of the disease, 
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contributing to most morbidity and mortality. Artemisinin-based combination therapy 
(ACT) remains the World Health Organization’s recommended antimalarial treatment due 
to the potent and fast activity of artemisinin (ART) and its derivatives to clear parasites. 
Pairing these drugs with slower acting antimalarials increases the effectiveness of 
treatment while reducing the risk of recrudescence and resistance that often follows 
monotherapy. Despite global efforts to circumvent this, ART resistance is developing as 
an emerging threat and has been a target of interest especially in the Southeast Asia 
region of Thailand and Cambodia where it is spreading [176].  
Dormancy is characterized by a stress induced growth arrest in the asexual ring 
stages, and has been proposed as a mechanism for drug evasion and subsequent 
recrudescence following removal of drug pressure [97]. Early development is arrested as 
dormant forms take on morphology characterized by a condensed nuclei and reduced 
cytoplasm. ART drugs have been demonstrated to induce this at high concentrations 
(700nM) in vitro [99, 177]. In vitro recrudescence follows removal of drug as parasitemia 
increases to detectable levels [98, 100]. Dormant parasites are not completely quiescent 
as low levels of metabolic activity are maintained, especially in the case of fatty acid 
synthesis and pyruvate metabolism [98, 100]. In vivo evidence of dormant parasites is 
also supported following artesunate treatment to P. vinckei petteri and P. v. vinckei in a 
rodent model [109]. Growth was arrested and micrographs revealed forms reminiscent of 
dormant P. falciparum parasites. More recently the antifolate, pyrimethamine, has been 
shown to induce a second cycle dormancy in daughter rings following exposure in the 
previous life cycle [102]. 
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Growth arrest is not exclusive to Plasmodium as a related phenomenon is 
observed in plants where dormancy has been previously described [178]. This can be 
triggered by abiotic stress (drought, salinity, temperature) and results in an early 
developmental arrest that confers protection from unfavorable conditions that might 
otherwise disrupt seed or bud development and kill the young plant. This is regulated by 
a network of signaling hormones that include abscisic acid (ABA) and gibberellic acid 
(GA) that work antagonistically to promote and release dormancy [179, 180].  
Apicomplexa organisms share a common ancestral origin with plants which may 
account for similarities. This comes in the form of the apicoplast, a non-photosynthetic 
organelle evolutionarily obtained following a secondary endosymbiotic relationship 
between a eukaryote and red algae. This is evidenced by its four membranes and shared 
metabolic pathways [153, 181]. The apicoplast’s sole essential function in the erythrocytic 
stages is to synthesize isoprenoids [155]. This occurs via the non-mevalonate pathway 
using pyruvate and glyceraldehyde 3-phosphate as starting materials and has been 
conserved across plastids [80].  
Dormancy may be a mechanism conserved and shared between Plasmodium and 
plant organisms. In this study, we explored dormancy regulating phytohormones in in vitro 
dormant parasites and observed an early recrudescence phenotype across several 
strains of P. falciparum. We also show the importance of isoprenoids in the recovery of 
dormant forms with and without an apicoplast. Together these findings help shed light on 
a mechanism that is not fully understood. 
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Materials and Methods 
In vitro Plasmodium falciparum culture  
Lab strains W2 (Indochina), 3D7 (Netherlands), D10-ACPLEADER-GFP (MRA-568), 
and ARC08-88 (11G) (Cambodia patient isolate) [182] were maintained in culture using 
previously described methods [12]. Cultures were maintained in complete medium 
consisting of RPMI-1640, 0.5% Albumax II, 0.2% sodium bicarbonate, 50 mg/L 
hypoxanthine, 25 mM HEPES and 2% O+ human red blood cells (RBCs; Interstate Blood 
Bank, Memphis, TN). D10 was cultured in the presence of 100 nM pyrimethamine. For 
dormancy experiments and drug assays, cultures were synchronized to ring stage using 
5% (wt/vol) D-Sorbitol (Sigma-Aldrich) and washed three times with RPMI [183]. 
 
Dormancy induction 
Dormancy was induced by adding 700 nM dihydroartemisin (DHA) to synchronized 
rings. Parasitemia was adjusted to 2% in 4% hematocrit and parasites were exposed to 
DHA for 6 hours except where noted. After DHA was washed out, 100 μM (±)-abscisic 
acid (Acros Chemicals), 50 μM fluridone (Sigma-Aldrich), or 10 μM gibberellic acid 
(Sigma-Aldrich) was added to culture. 1 mL of parasites were seeded in 12-well plates in 
duplicates. A sham control with vehicle (DMSO) was also grown in parallel. Giemsa-
stained thick and thin blood smears were obtained daily and used to monitor 
recrudescence and growth. Complete media was changed every 48 hours. Experiments 
were done with two replicates at least twice. 
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Drug susceptibility assays 
Drugs were serially diluted 1:2 in complete media in 96-well plates. 10 μL of drug 
was transferred to a new plate with 90 uL/well of synchronized ring-stage parasites at 
0.5% parasitemia and 2% hematocrit. After 48 hour incubation, 1 μCi of [3H] hypoxanthine 
monochloride was added to each well and allowed to incorporate for an additional 24 
hours. Plates were then frozen at -80 °C. For assays with artemisinin drugs, hypoxanthine 
was added at time 0 and allowed to incubate for 48 hour prior to freezing [98]. Plates were 
thawed, washed and harvested in a FilterMate cell harvester. 50 μL scintillation cocktail 
was added to each well and plates were read in a TopCount NXT scintillation counter. 
Data was imported into TriFox DataAspect Plate Manager software for calculation of 50% 
inhibitory concentration (IC50) and curve fitting analysis. 
 
Geranylgeranyl pyrophosphate (GGPP) rescue in isoprenoid-inhibited parasites 
Ring-stage synchronized luciferin expressing 3D7 was exposed to 1-100 μM 
fosmidomycin (FOS [Sigma-Aldrich]) to inhibit isoprenoid biosynthesis or pretreated with 
2 μM doxycycline (DOX [Sigma-Aldrich]) for 48 hours to generate parasites without an 
apicoplast [43]. Parasites were plated in 24-well plates at starting parasitemia of 0.5% in 
2% hematocrit. 200 μΜ isopentyl pyrophosphate trisammonium salt (IPP [Isoprenoids, 
LC]) or 0.02, 0.2, 2 or 20 μΜ geranylgeranyl pyrophosphate trisammonium salt (GGPP 
[Isoprenoids, LC]) was added to each drug treatment. A control with vehicle (ethanol) was 
also plated. Aliquots were taken daily and combined with 150 μg/mL D-luciferin (Perkin 
Elmer) for 10 minutes prior to luminescence reading on a TopCount NXT scintillation 
counter.  In a separate experiment, 2 μM GGPP was given to parasites treated with 5 μM 
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FOS. On day 4, GGPP was removed from one of these groups, while FOS was 
maintained in culture. Micrograph images were obtained daily. 
 
Isoprenoid inhibition in dormant parasites 
Synchronous ring stage D10-ACPLEADER-GFP parasites were pre-treated with 2 μM 
DOX for 48 hours and then sorbitol synchronized again. Parasitemia was adjusted to 2% 
in 4% hematocrit. 700 nM DHA was used to induce dormancy and this was washed out 
after 6 hours. 200 μΜ IPP, 2 μΜ GGPP, 100 μM ABA or 10 μM GA was added and 
maintained in the presence of DOX. In a separate experiment, 5 μM FOS was used to 
inhibit isoprenoid synthesis in dormant parasites. FOS was added at the same time as 
DHA and maintained in culture. 200 μΜ IPP or 2 μΜ GGPP were added following DHA 
removal and kept in media. Fluorescent images and slides were taken daily. 
 
Fluorescence microscopy 
For fluorescent images, D10-ACPLEADER-GFP parasites in 0.1% hematocrit were 
incubated with 1 μg/mL Hoescht 33342 nuclear stain and 50 μM MitoTracker Red 
CMXRos for 20 minutes at 37°C followed by 3 washes with RPMI.  Cells were 
resuspended in complete media and allowed to settle onto 8 chambered slides (Thermo 
Scientific) coated with 0.05 mg/mL poly-L-lysine. Images were obtained on a DeltaVision 
CORE microscope (Applied Precision) using a 100x objective. 
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Results 
Abscisic acid and gibberellic acid stimulate early recrudescence in dormant 
parasites 
Plant dormancy is a response to external stress during an early developmental 
stage regulated by endogenous hormones. Without confirmation that the same 
metabolites exist in Plasmodium, we aimed to determine what effect exogenous 
supplementation of phytohormones might have in influencing the response of parasites 
by first inducing dormancy in the early ring stages and then exposing them to the 
phytohormones. Initially 100 µM ABA was supplemented to DHA-induced dormant 
parasites and maintained in culture media. Daily thick and thin blood smears were 
collected and examined microscopically for parasites exhibiting normal morphology 
(rings, trophozoites, schizonts) compared to dead and dormant forms. The ratio of normal 
to total (normal + dead/dormant forms) was used to monitor recovery.  Following DHA 
exposure, all 3D7 parasites had become dead or dormant within 24 hours. Normal 
parasite morphology was first observed by day 3 in cultures treated with ABA. This occurs 
about 24 hours earlier than groups which had only been exposed to DHA. While initial 
growth is first observed when exposed to ABA, parasites did not grow any faster (Figure 
2.1A). The same effect is observed with W2 parasites (Figure 2.1B). If 50 µM fluridone 
(FLD), an ABA inhibitor, is supplemented to parasites following dormancy induction and 
removed on day 2, recovery is delayed by at least 2 days (Figure 2.1C). 
We next explored the effects of gibberellic acid (GA). GA promotes germination of 
the seed in plants and acts to release them from dormancy. One would expect it to act 
antagonistically with ABA but when GA was supplemented in the same manner as ABA, 
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we observed a similar response. GA-treated parasites showed initial signs of normal 
morphology 48 hours earlier than DHA alone. This effect is achieved with 10 µM GA, 
making it more potent and efficient at stimulating recovery than ABA (Figure 2.2). 
 
Fluridone causes a delay in recrudescence of dormant parasites 
Fluridone is an herbicide that binds to phytoene desaturase and inhibits carotenoid 
and ABA biosynthesis [184]. It acts on seeds to reverse the effect of ABA and releases 
them from dormancy. When dormant parasites are exposed to this for 2 days, 
recrudescence is delayed and the antagonism with ABA is maintained. We aimed to 
further explore FLD’s dormancy promoting effects through prolonged exposure to it. 
Dormancy was induced with DHA and 50 µM FLD was added following the wash and 
removed at varying time points (days 2, 8, 10, and 12). FLD prevents recovery as all 
dormant parasites fail to recrudesce in its presence. If FLD is removed 2 to 8 days post-
dormancy induction, parasites start recrudescing 2 to 4 days later. After 8 days, removing 
FLD does not have an effect as these parasites fail to recover and clear out of culture 
(Figure 2.3). 
 
An artemisinin resistant patient isolate displays an early recrudescence phenotype 
when exposed to ABA and GA 
ABA, GA and FLD all have an observable effect on DHA-induced dormancy of 
standard lab strain parasites but can that be replicated in an artemisinin-resistant patient 
isolate? To answer our question, we ran similar experiments with ARC08-88 (11G), a 
clone from patient isolate ARC08-88, which carries the Kelch 13 (K13) mutation [182]. 
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Multiple point mutations in the propeller domains of the Kelch gene on chromosome 13 
(PF3D7_1343700) are associated with a delayed parasite clearance phenotype and 
serve as a molecular marker for the spread of artemisinin resistance [92]. Because of its 
resistance compared to W2 (Table 1), parasites were given two doses of 700 nM DHA 
(at time 0 and 24 H) over 48 hours. ABA, GA and FLD were then added and FLD was 
washed out after 48 hours. All parasites had arrested growth by day 3. Signs of normal 
morphology was detectable in culture by day 8 in the GA-treated group and day 9 in the 
ABA-treated group (Figure 2.4). Those exposed to just DHA showed signs of recovery on 
day 10.  FLD-treated parasites once again exhibited a delay with recovery beginning on 
day 14. The findings of this suggest that the effects of the phytohormones are 
independent of artemisinin resistance. 
 
The apicoplast is required for recrudescence 
Isoprenoid biosynthesis in the blood stages of Plasmodium, is the apicoplast’s only 
essential function and inhibiting this has a direct effect on parasite viability. We explored 
the apicoplast’s role in recrudescence of dormant parasites to determine if it was required 
for recovery. Exposure to antibiotics such as doxycycline (DOX) results in parasites that 
are unable to replicate an apicoplast in the second life cycle and experience a delayed 
death effect [43]. All apicoplast related metabolism is disrupted, including production of 
essential isoprenoids. Fosmidomycin (FOS) inhibits isoprenoid biosynthesis and results 
in death in the first life cycle. In either case, parasites can be rescued with 200 µM IPP 
supplementation [155]. The IC50 value for FOS in 3D7 is 1.25 ± 0.05 µM [185]. We found 
that growth is sustained in parasites 5 µM  FOS in the presence of GGPP and they die 
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when it is removed (Figure 2.5A, B). Additionally, treating parasites with 0.2 – 2.0 µM 
GGPP can rescue up to 10 µM FOS (Figure 2.6A, B). There is observed toxicity at higher 
concentrations of GGPP and lower concentrations are ineffective. Previous work has 
shown that 20 µM of geranylgeraniol, the alcohol analog of GGPP, rescues at 10 µM FOS 
[155]. GGPP supplementation is not sufficient enough to rescue DOX-treated parasites 
as they are able to progress into the second life cycle but die by day 4 (Figure 2.7). 
D10-ACPLEADER-GFP was used in the experiments because it has a GFP tagged 
acyl carrier protein that localizes to the apicoplast [186]. This can be visualized in dormant 
and recovering parasites for confirmation of apicoplast presence or absence. 48 hour pre-
treatment with DOX was used to generate ring-stage parasites without the organelle, and 
these parasites were then exposed to DHA to induce dormancy.  ABA, GA, IPP or GGPP 
was then added. IPP was also added four days after inducing dormancy in a separate 
group to assess the effect that delaying exposure to the isoprenoid might have. Parasites 
without an apicoplast only recovered when exposed to IPP, while ABA and GA treated 
parasites remained dormant (Figure 2.8A). For parasites which received IPP on day 4, 
normal morphology became visible by day 7 (Figure 2.8B).  Fluorescent imaging 
confirmed that the DOX-treated parasites lacked an intact apicoplast yet were still able to 
recover in the presence of IPP (Figure 2.9). Mitotracker staining revealed weakly detected 
signals in dormant parasites that were blurry and lacked distinct morphology like actively 
growing parasites. GGPP also failed to cause recovery in DOX-treated dormant parasites 
(Figure 2.10). 
The previous results with IPP prompted us to explore if the addition of it is time 
dependent. DOX treated parasites were given IPP at the start, days 4, 8 and 16 post-
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dormancy induction. Parasites supplemented with IPP up to day 8 eventually recovered 
(Figure 2.11A). The length of time it takes for parasites to be visible is extended, showing 
up 10 days later when IPP is added on day 8 compared to when its added on day 4. GFP 
signal was lost in some parasites later in the experiment. This is possibly due to not 
culturing with pyrimethamine, which D10 is resistant to due to the selectable marker of 
the original insert, for the duration of the experiment (Figure 2.11B). If IPP is added on 
day 16, recovery was not observed. By day 30, all dormant/dead forms had been cleared 
from culture.  
 
GGPP and IPP supplemented parasites fully recrudesce in FOS-treated parasites  
 
We also wanted to investigate dormancy in parasites that had isoprenoid 
biosynthesis inhibited but maintained an intact apicoplast. Initially 5 µM FOS, which 
inhibits DOXP reductoisomerase of the isoprenoid biosynthetic pathway, was added at 
the start and maintained in media for the duration of the experiment. DHA was used to 
induce dormancy as previously described. These parasites were also supplemented with 
either 200 µM IPP or 2 µM GGPP. All parasites exited dormancy but only fully 
recrudesced in the presence of IPP or GGPP (Figure 2.12A). Parasites exposed to FOS 
alone, failed to progress past initial asexual life cycle and were killed (Figure 2.12B).  
 
Discussion 
Exploring plant biology offers an alternative avenue to further understand a survival 
mechanism shared amongst both organisms that may have been evolutionarily passed 
down. Dormancy has long been established in plants as an early developmental process 
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that ensures viability of a young seed or embryo. The growth arrest triggered by external 
forces under unfavorable conditions confers protection against stress that might kill or 
interfere with that development. This isn’t entirely unlike what is observed with other 
organisms. The concept of dormancy within the blood stages of P. falciparum was first 
reported after parasites resumed growth following drug removal (Kyle and Webster 1996). 
Exposure to the ring stages with artemisinins have been able to induce this in vitro [98, 
99]. The molecular mechanisms underlying how parasites enter and exit a state of 
dormancy are far less defined than they are in plant organisms and thus represent a gap 
in our understanding. Dormancy may be contributing to antimalarial drug resistance that 
develops, so elucidating this is vital. The scope of this study involved utilizing what is 
known about how regulatory hormones influence plant dormancy and correlating that to 
P. falciparum dormancy in addition to further analyzing the importance of the apicoplast 
on recovery. In this study we demonstrate that parasites are released from dormancy 
earlier when exposed to ABA or GA. Furthermore the apicoplast and specifically the 
isoprenoids it produces are essential for recovery in dormant parasites. 
The strongest connection between parasites and higher plant organisms is the 
apicoplast. This organelle establishes an evolutionary link between very different 
organisms that nonetheless share biology. Several genes, proteins, mechanisms and 
biological functions have remained and that is apparent when comparing homology of the 
plastids [187]. The MEP and carotenoids pathways have both been conserved. Not all 
functionality has though as photosynthesis has been lost as intracellular parasites do not 
need it.   
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The first phytohormone we looked at was ABA as it is the primary dormancy 
regulator in plants. As a signaling hormone, ABA senses stress (e.g. onset of cold weather 
during winter, water drought) and accumulates, inducing a dormant response to prevent 
germination, an outgrowth of an embryo from the seed [188]. This occurs during 
secondary dormancy after a seed has been released from the mother plant. Dormancy is 
maintained as long as ABA levels are kept high. In this context it protects the seed from 
conditions that would inhibit development and/or kill it. Interestingly enough ABA does not 
work in the same way with P. falciparum. Supplementing dormant parasites with it 
encourages recovery as opposed to maintaining dormancy. This was observed with 
several dormant strains (W2, 3D7, D10-ACPLEADER) as microscopic signs of normal 
morphology was seen 24 hours before control groups. An important question is why ABA 
seems to function differently here. Difference in functionality may be attributed to 
evolutionary adaptations to how ABA is utilized in a different organism more complex than 
plants. Maternal ABA produced by the mother plant and transferred to the seed is unable 
to induce dormancy but rather promotes embryo growth [189, 190]. It is ABA produced 
by the seedling that induces dormancy. The effect we are observing may be analogous 
to how seeds of some plants are influenced by exogenous ABA. We also have data 
suggesting that ABA is produced in the blood stages of asynchronous P. falciparum 
(Chapter 3). Confirmation of ABA biosynthesis in dormant parasites might help us discern 
between any differences between endogenous versus exogenous ABA effects. Initially 
we tested ABA in dormant parasites using nanomolar concentrations ranging from 1 nM 
to 100 nM. No effect was observed at these levels (data not shown). An effect was 
observed when 100 μM was used. 
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For parasites to be able to utilize supplemented ABA, there must be able to have 
a mechanism to reach the parasite which would be crossing two membranes, the host 
erythrocyte and parasite itself. A human anion transporter, Band 3, is expressed on red 
blood cells and ABA uses it for entry into the host [191]. G protein α subunit GPA1 has 
been identified as a plasma membrane receptor for ABA in Arabidopsis and yeast [192]. 
These transporters have not been reported in Plasmodium and a search on PlasmoDB 
did not reveal potential candidates. What if ay ABA specific receptors exist is unknown. 
We don’t fully understand the mechanism behind how ABA was able to stimulate 
dormancy release. Our knowledge of the role of abscisic acid in Plasmodium is limited 
and the earliest clues were first reported in related Apicomplexan parasite, Toxoplasma 
gondii. T. gondii has been a model organism used to study other Apicomplexans due to 
its relative ease of genetic manipulation, short life cycle and availability of many cell 
markers. Nagamune et al. detected endogenous ABA in parasite extracts and studied its 
effects on development [163]. T. gondii exists in two forms within humans, tachyzoites 
and bradyzoites. Bradyzoites are cyst forms that go dormant as a response to stress 
induced by host immune reaction. These dormant forms are protected and unaffected by 
most drugs, similar to dormant P. falciparum.  Within T. gondii, supplementation with 
exogenous ABA mediates calcium (Ca2+) release by inducing production of second-
messenger cyclic ADP ribose (cADPR) [163]. This leads to elevated levels of intracellular 
Ca2+ that stimulates protein secretion required for development and egress. Ca2+ is 
required for asexual Plasmodium growth and invasion of erythrocytes [193]. Transient 
receptor potential (Trp) channel homologs and IP3 for Ca2+ release have been identified 
in Plasmodium spp [194, 195]. Ca2+ mediated release by ABA could be a possible theory 
54 
 
to explain its mechanism in P. falciparum but more work will need to be done to confirm 
this.  
Several studies have also reported the presence of ABA in other eukaryotic cells. 
ABA’s connection to cADPR and Ca2+ appears to be conserved across many species and 
consistent to an additional functionality it has in plants [166]. It’s also been implicated in 
human granulocytes as a pro-inflammatory cytokine that stimulates cADPR and 
subsequent increase in intracellular Ca2+ [164]. ABA has been found in low 
concentrations in some mammalian cells. It is found in human plasma depending on diet 
consumption and therefore there was initial concern that parasites might scavenge it from 
host cells. To reduce this risk, experiments were cultured with Albumax, a synthetic 
culture media supplement, as opposed to human plasma. 
ABA is the primary dormancy inducer in plants, whereas GA is the primary 
dormancy releaser. They have opposing roles as a decrease in ABA levels in seeds is 
associated with an increase in GA which stimulates germination. In our experiments, GA 
not only was able to stimulate early release from dormancy, it did so at 10 fold 
concentration less than ABA at about 24 hours earlier (Figure 2.2). This result was 
somewhat surprising because the two are antagonistic in plants. During seed 
development, GA ends dormancy and promotes germination and growth [179, 196]. Very 
little work has been published investigating gibberellins with Apicomplexans. GA, along 
with other growth promoters, has been previously investigated for its effect on P. 
falciparum parasites. The hormone was found to increase the parasite multiplication rate 
resulting in higher parasitemia when supplemented to blood stage cultures [197]. This 
role as a growth promoter might help explain why its effect on dormant parasites is more 
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pronounced than ABA. Different gibberellin biosynthetic inhibitors (inabenfide and AMO-
1618) are effective at killing P. falciparum parasites by causing cells to swell and rupture 
[198]. As a growth promoter, GA might be stimulating P. falciparum growth signals in 
dormant parasites to release from the growth arrest induced during dormancy. In plants, 
the hormone is theorized to activate enzymes that release dormancy [122]. Proteins 
associated with recrudescence are unknown but phytohormone influence on expression 
might help reveal upregulation in genes that are key to this process. 
The results with FLD are not entirely unexpected. As an inhibitor, it has an 
antagonistic effect with ABA. It was not surprising that it would have the opposite effect 
from ABA by keeping parasites dormant with exposure, but releasing them upon removal. 
FLD is an ABA inhibitor with antagonistic role in plants and T.gondii. While it releases 
seeds from dormancy, it actually induces a dormant response in T.gondii.  FLD induces 
formation of dormant bradyzoite forms that encyst and grow slowly [163]. Addition of FLD 
to our culture prevents them from recrudescing but this can be reversed if FLD is 
removed. However, supplementing ABA to FLD-treated parasites was unable to reverse 
this. We also explored the effect of constant FLD pressure on non-dormant cultures. 
Progression through life cycle was slow and parasitemia remained low but dormant 
parasites did not develop (Figure A1). 
Resistant parasites lose their sensitivity to antimalarials and dormancy is theorized 
to be a mechanism that helps promote this by selecting for parasites that have become 
resistant. We aimed to explore whether the observed phythormone effects were unique 
to sensitive strains or if they could be replicated with an artemisinin-resistant strain with 
longer innate recovery. ARC08-88(11G), a clinically relevant artemisinin-clone of ARC08-
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88 from Cambodia was selected. Its resistance is conferred by presence of the K13 
mutation and it exhibits a similar in vitro dormancy phenotype as other strains exposed to 
DHA. There was no difference detected in how it responded to ABA or FLD exposure 
when dormant. This suggests that the response is independent of artemisinin resistance. 
48 hour FLD exposure resulted in parasites that emerged from dormancy on day 14, 
which was four days later than the groups exposed to only DHA. This is prolonged from 
W2 and 3D7, where FLD causes a two day delay in recrudescence.  
Isoprenoids are a large class of molecules found in all living organisms. The 
apicoplast is required for isoprenoid biosynthesis, and ABA and GA, the two primary 
dormancy regulating hormones are derived from isoprenoids in plant species. In 
Plasmodium, they serve as building blocks for many metabolites such as ubiquinone and 
are vital for various cellular functions [158, 199, 200]. They are essential for parasite 
survival in the blood stages, but this has not been examined in dormant forms for viability. 
In this study, we aimed to explore how essential the apicoplast and isoprenoids were to 
recovery of dormant parasites. The apicoplast is an interesting organelle that has served 
as a target for antimalarial development because it is the site of isoprenoid biosynthesis. 
We exploited the fact that IPP can compensate for isoprenoid inhibition in apicoplast-
deficient parasites and those that had the biosynthetic pathway directly disrupted with 
fosmidomycin [155]. We have observed that downstream product, 20-carbon GGPP, can 
achieve the same effect at lower concentrations when exposed to up to 10 FOS. GGPP 
is used for carotenoid formation, geranylgeranyl prenylation of proteins.  
The first approach involved inducing dormancy in apicoplast-deficient parasites. 
Our results show that the apicoplast is required for recrudescence. In the absence of the 
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organelle, parasites fail to recover but this may be overcome with IPP supplementation. 
ABA, GA, and GGPP alone do not appear to be sufficient enough to promote recovery 
from dormancy without the apicoplast present. This result was surprising, because initially 
we expected parasites exposed to ABA and GA to exit dormancy, but then die as neither 
can compensate for isoprenoid absence. Apicoplast-deficient parasites can survive up to 
3 days supplemented with GGPP before dying. However these parasites do not exit 
dormancy in the presence of GGPP.  This suggests that IPP plays a larger role in recovery 
and isoprenoid products not derived specifically from GGPP are necessary to “awaken” 
parasites and maintain growth. IPP is the basic precursor for all isoprenoid products and 
a network of these may be needed to exit and survive. One possible explanation is 
mitochondrion function. IPP is a precursor of ubiquinone, an essential metabolite of the 
electron transport chain. Dormant parasites exhibited low mitochondrial membrane 
potential when stained with Mitotracker. In a previous study, exposure to atovaquone, an 
inhibitor of the QO site of cytochrome b, resulted in delayed recovery of dormant parasites 
[101]. Low levels of pyruvate metabolism are maintained in dormant parasites [100]. 
Pyruvate serves as one of the starting material for IPP production so this may possibly 
be ramped up in dormant parasites as they prepare to exit dormancy.  
We also noted that dormant parasites can remain viable for up to 8 days without 
the organelle as long as IPP is supplemented by day 8. This helped confirm that they 
were not dead, but had their development arrested in a dormant state. Interestingly 
dormant parasites also remained viable for 8 days while under FLD pressure. Removal 
past that point resulted in parasites that did not recrudesce.  
58 
 
Our second approach to inhibiting isoprenoid biosynthesis in dormancy involved 
using FOS to directly target DXR in the apicoplast, preventing the pathway from 
completion. These parasites retained the organelle and with it present, recrudescence 
followed DHA exposure. Merely inhibiting isoprenoid production does not prevent a 
release from their dormant state. However IPP or GGPP was required for full recovery. 
This is due to the toxic activity of FOS which parasites are protected from while dormant, 
but become susceptible to as rings that re-emerge. At this stage, isoprenoids are needed 
to reverse the drug’s effect. A higher percentage of trophozoites and schizonts were 
observed to exit dormancy in the FOS only groups. The few rings that were observed 
were likely parasites that had just emerged from dormancy and not newly invaded 
parasites from these schizonts. 5 μM FOS may not be sufficient for a complete block of 
isoprenoid inhibition and therefore there may be a small amount of IPP present in the 
parasites before they go dormant which might be used to recover. 
Recently ABA was used to investigate malaria disease severity and parasite 
transmission in mosquito and mouse host using P. yoelii [201]. The authors saw a 
reduction in blood parasitemia and gametocytemia following ABA supplementation as 
well as reduced transmission to mosquitos. It was determined that this decrease was 
likely due to ABA stimulating the host’s immune system after exploring in vitro effects with 
P. falciparum. There was no direct effect on in vitro development of the parasite as 
asexual growth nor were gametocyte formation altered. This is consistent with ABA 
exposure we’ve done across several life cycles of 3D7 (Figure A2). This study sheds light 
on the effect of the hormone on host systems, which ABA affects and in turn reduces 
parasite burden. Combined with its effect on dormancy, ABA could work to stimulate 
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recrudescence and reduce parasite burden by further stimulating the host’s immune 
response to help clear those residual parasites. 
The findings of this study could potential have larger implications on dormant forms 
seen in different Plasmodium species. The hypnozoites of P. vivax in hepatocytes remain 
elusive as the precise mechanism behind their formations and subsequent relapses are 
not fully understood. Further work will need to be done to examine any effect that 
phytohormones may have in regulating dormancy in the liver stages. If ABA and/or GA 
are able to stimulate a release from dormancy, theoretically a drug with good liver stage 
activity could be used to clear infection. This is important as the number of antimalarials 
that are able to target and effectively treat hypnozoites is limited. 
In summary, enhancing our knowledge of dormancy and how it contributes to drug 
resistance and evasion of P. falciparum will be important moving forward. The precise 
mechanism behind how ABA and GA influence dormant parasites is not fully understood 
but they may help further shed light on this survival mechanism. The apicoplast and IPP 
also play important roles that are key to recrudescing and surviving following dormancy 
induction by DHA. 
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Figure 2.1. Effect of ABA in DHA-induced dormant parasites. (A) Synchronized 3D7 
parasites were exposed to DHA for 6 h to induce dormancy. Following 3 times wash with 
RPMI, 100 µM ABA was added and maintained in culture. Recovery was monitored in 
Giemsa-stained blood smears and ratio of normal to total (dormant/dead + normal) 
parasites was recorded. ABA supplemented parasites recovered earlier than parasites 
which were simply given DHA. (B) A similar pattern is observed with W2. When 50 µM 
FLD is supplemented and removed on day 2, parasites begin to emerge from dormancy 
2 days later. (C) Micrograph images reveal normal parasites in smears of ABA 
supplemented parasites 24 h earlier than DHA only parasites and 48 h later in FLD 
supplemented parasites. Bars represent ± SEM 
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Figure 2.2. GA exposure leads to dormant parasites to recrudesce early. Dormant 
parasites supplemented with 10 µM GA exhibited earlier signs of recovery than when 
supplemented with ABA. Bars represent ± SEM 
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Figure 2.3. Effect of FLD in DHA-induced dormant parasites. (A) FLD was added to 
dormant parasites and removed at different intervals. Dormancy is maintained in the 
presence of FLD, but can be reversed upon its removal up to 8 days. Parasites exposed 
to FLD longer than 8 days fail to recover. Bars represent ± SEM 
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Figure 2.4. ABA, GA and FLD display similar patterns with ARC088-88 (11G). 
Artemisinin resistant Cambodian patient isolate ARC08-88 (11G). DHA was added at T=0 
and 24 h and parasites were under drug pressure for a total of 48 h. After washing, ABA, 
GA and FLD were added with FLD being washed out after 48 additional hours. Dormant 
parasites began to exit on day 10, but when exposed to GA and ABA, parasites started 
to wake up on days 8 and 9, respectively. A delay with FLD is observed as normal 
parasites emerge starting on day 14. Bars represent ± SEM 
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Figure 2.5.  GGPP rescue in FOS-treated parasites.  (A) 2 µM GGPP rescues parasites 
exposed to 5 µM FOS. Parasites exposed to FOS fail to produce merozoites and do not 
complete the life cycle. This is reversed with GGPP. (B) When GGPP is removed, the 
toxic effects of FOS take over and kill parasites. Values are normalized to an untreated 
control. Bars represent ± SEM  
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Figure 2.6. GGPP rescue over wider range of FOS. (A) Rescue was explored in 
parasites exposed to a range of FOS and GGPP. Ring-stage forms matching control were 
observed at 96 hours when 10 µM FOS-treated parasites were given 0.2 and 2.0 µM 
GGPP. (B) Toxicity is observed with 20 µM GGPP. RLU = relative luminescence units; 
Bars represent ± SEM 
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Figure 2.7. GGPP is not as effective at rescuing in DOX-treated parasites. Parasites 
were pre-treated with DOX for 48 hours to produce parasites without an apicoplast. 
Different concentrations of GGPP as well as an IPP control were added simultaneous 
with DOX treatment. GGPP parasites survive up to 3 days with as little as 0.2 µM GGPP 
but die by day 4. Growth is sustained in the presence of IPP. Bars represent ± SEM 
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Figure 2.8. Apicoplast-deficient dormant parasites only recover when 
supplemented with IPP. (A) Parasites were pretreated with DOX 48 hours prior to DHA 
exposure to generate daughter parasites which lacked an apicoplast. DOX was 
maintained in culture and IPP, GA and ABA were added for the duration of the 
experiment. IPP was also added 4 days later. Only when supplemented with IPP did those 
parasites recover. (B) Micrograph images reveal dormant forms in DHA+DOX treated 
groups with signs of recovery in groups supplemented with IPP. Recrudescence was 
observed in fluorescent images. The lack of localization of GFP signal is due to absence 
of an apicoplast for the acyl carrier protein to localize to. These parasites are still able to 
exit dormancy and proliferate due to the presence of IPP. Bars represent ± SEM 
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Figure 2.9. Apicoplast-deficient dormant parasites only recover when 
supplemented with IPP. Recrudescence was observed in fluorescent images. The lack 
of localization of GFP signal is due to absence of an apicoplast for the acyl carrier protein 
to localize to. These parasites are still able to exit dormancy and proliferate due to the 
presence of IPP.  
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Figure 2.10. Apicoplast-deficient dormant parasites fail to recover when 
supplemented with GGPP. In the absence of an apicoplast, 2 uM GGPP is not sufficient 
enough for recovery from dormancy. Following DHA treatment, GGPP was added, but no 
active parasites were observed in blood smears. Bars represent ± SEM 
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B 
Figure 2.11. Parasites recrudesce when IPP supplementation is delayed. (A) DOX 
was maintained in dormant cultures and IPP was added either at the start, 4, 8 or 16 days 
post dormancy induction. If parasites are supplemented with IPP after 8 days, signs of 
normal parasites can be observed by day 19. Adding IPP 16 days later appears to be too 
late as those parasites never recovered. (B) Fluorescent images of parasites with IPP 
added on day 8 reveal growing parasites. Bars represent ± SEM 
  
71 
 
A 
0 2 4 6 8 10 12
0
20
40
60
80
100
DHA
DHA+FOS
DHA+FOS+GGPP
DHA+FOS+IPP
Days
N
or
m
al
/T
ot
al
 P
ar
as
ite
s
 
 
B 
DHA
0 1 2 3 4 5 6 7 8 9 10 11
0
20
40
60
80
100
Days
st
ag
e 
pr
es
en
t (
%
)
DHA+FOS
0 1 2 3 4 5 6 7 8 9 10 11
0
20
40
60
80
100
Days
st
ag
e 
pr
es
en
t (
%
)
DHA+FOS+GGPP
0 1 2 3 4 5 6 7 8 9 10 11
0
20
40
60
80
100
Days
st
ag
e 
pr
es
en
t (
%
)
DHA+FOS+IPP
0 1 2 3 4 5 6 7 8 9 10 11
0
20
40
60
80
100
Days
st
ag
e 
pr
es
en
t (
%
)
ring
trophozoite/schizont
dormant/dead
 
 
Figure 2.12. Inhibiting isoprenoid biosynthesis does not prevent parasites from 
exiting dormancy. Ring stage parasites were given DHA to induce dormancy as well as 
FOS which inhibits all isoprenoid biosynthesis, while maintaining an apicoplast. 200 µM 
IPP or 2 µM GGPP was then added. All parasites exited dormancy, however complete 
recrudescence was only observed in FOS-treated parasites supplemented with IPP or 
GGPP. Without either, the effects of FOS kill the parasites as they start to recover. Bars 
represent ± SEM 
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Table 2.1. Artemisinin derivatives 
 
 
  
Strain 
IC50 (±SD) ng/mL 
Artelinic 
acid artesunate dihydroartemisinin artemisinin 
ARC08-88 (11G) 86.5 (±48.5) 7.0 (±3.4) 2.0 (±0.38) 17.6 (±4.5) 
W2 20.4 (±13.2) 3.9 (±3.5) 1.3 (±0.53) 6.9 (±1.16) 
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Chapter 3 
Characterization of abscisic acid biosynthesis in Plasmodium falciparum 
 
Abstract 
Abscisic acid (ABA) is a plant hormone found in many organisms that plays a role 
in regulating dormancy, calcium signaling and responding to stress. Isoprenoid 
precursors of ABA are synthesized in the apicoplast, an ancient plastid evolutionary 
passed down from a secondary endosymbiotic relationship between cyanobacterium and 
red algae. Several metabolic pathways are common to Apicomplexan parasites and 
higher plant organisms including type II fatty acid synthesis and the methylerythritol 
phosphate (MEP) pathway for isoprenoid biosynthesis. Among the many metabolites 
derived from isoprenoid, are carotenoids, pigments with antioxidant properties. 
Carotenoid biosynthesis derived from the 20-carbon isoprenoid, geranylgeranyl 
pyrophosphate (GGPP), is found in Plasmodium falciparum, similar to its presence in 
plants. Here we establish an approach to synthesize 13C3-GGPP and use it to 
metabolically label this pathway in order to identify and confirm abscisic acid biosynthesis 
in the erythrocytic stages of P. falciparum. 
 
Introduction 
The Apicomplexan apicoplast is the site of isoprenoid biosynthesis and this 
proceeds via the MEP pathway common to other plastid bearing organisms. Isoprenoids 
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represent a large class of molecules found in all living organisms that are essential 
components of thousands of secondary metabolites. Multiple chains of isopentyl 
pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP) bind together to form 
diverse compounds that are utilized for various functions. The 20-carbon geranylgeranyl 
pyrophosphate (GGPP), consisting of four isoprene units, is produced by head to tail 
condensation of IPP to an allylic primer such as DMAPP. This serves as an essential 
precursor for biosynthesis of ubiquinones, dolichols, several terpenes and terpenoids, 
including carotenoids, gibberellins and chlorophylls [202]. It is also used in the prenylation 
of proteins when a geranylgeranyltransferase transfers geranylgeranyl groups to the C-
terminus of proteins. This posttranslational modification grants proteins biological activity 
that may have regulatory or structural functions in cell growth, differentiation, membrane 
movement or vesicle transport [203]. 
Of special interest is IPP’s role as the basic precursor of carotenoid biosynthesis. 
Carotenoids are lipophilic pigments with antioxidant activity that are involved in 
scavenging free radicals and light absorption. Two molecules of GGPP condense to form 
phytoene, a 40-carbon long chain terpenoid that serves as the backbone for all 
carotenoids. Synthesis of this represents the first committed step in the pathway and is 
catalyzed by phytoene synthase. Different carotenoids are formed through alterations of 
the base structure and addition of oxygen groups [157]. 9-cis-violaxanthin and 9-cis 
neoxanthoxin are shuttled out of the plastid into the cytosol where they are catabolized to 
the 15-carbon xanthoxin. Rearrangement of this structure will yield the sesquiterpene, 
abscisic acid (ABA). Evidence of carotenoid biosynthesis in P. falciparum was previously 
reported using [1-3H] GGPP as a metabolic label [158]. Several carotenoids common to 
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plants such as phytoene, lutein, and β-carotene were also identified, in addition to an 
enzyme (PfB0130w) with phytoene synthase activity. Treatment with norflurazon (NFZ), 
a potent phytone desaturase (PDS) inhibitor in plants, led to an accumulation of phytoene 
and reduced downstreams levels of carotenoids in parasites. ABA biosynthesis however 
has not been confirmed (Figure 3.1). 
ABA serves as a regulator of dormancy in plants as well as has additional functions 
as a stress sensor and calcium agonist. We’ve shown that supplementing it to dormant 
Plasmodium falciparum parasites results in stimulating early recovery from dormancy 
(Chapter 2). To date the only evidence that ABA is found in Apicomplexan parasites 
comes from work done on Toxoplasma gondii. ABA was detected in parasite extracts 
using gas-chromatography mass spectroscopy and it plays a role in parasite development 
and egress from host cell [163]. Fluridone (FLD), an herbicide inhibitor of carotenoid 
biosynthesis, was found to reduce levels of ABA and stimulate formation of dormant cysts. 
In this study, we hypothesized that the biosynthetic pathway to produce ABA has 
been retained in Plasmodium. We aimed to confirm and characterize this in the blood 
stages of P. falciparum using 13C3-GGPP to metabolically label the pathway. The novelty 
of our approach comes from having a label on three of the isoprene units that make up 
the molecule by first synthesizing 13C-IPP, and then using a GGPP synthase to create 
13C3-GGPP from 13C-IPP and DMAPP. We show for the first time GGPP synthesized with 
three 13C labels in order to metabolically label the carotenoid pathway and confirm ABA 
production. 
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Materials and Methods 
In vitro Plasmodium falciparum culture  
Lab strains W2 and 3D7 were maintained in culture using previously described 
methods [12]. Cultures were maintained in complete medium consisting of RPMI-1640, 
0.5% Albumax II, 0.2% sodium bicarbonate, 50 mg/L hypoxanthine, 25 mM HEPES and 
2% O+ human red blood cells (RBCs; Interstate Blood Bank, Memphis, TN) at 37 ºC 
 
Gas-chromatography mass spectroscopy analysis of P. falciparum extracts 
1 mL asynchronous 3D7 culture was incubated in 12-well plates at 2% parasitemia 
in 4% hematocrit. 10 µM clindamycin (CLI), 5 µM chloramphenicol (CAM), and 5 µM 
mirincamycin (MIR) were added to wells. Fluridone was added at concentration of 50 µM. 
A control with 0.1% DMSO and untreated RBC samples were also prepared. This was 
done in triplicate. After 24 hours, erythrocytes were lysed with 0.5% saponin and washed 
three times with PBS at 4 ºC. Samples were then stored in -80 ºC prior to analysis. 
A quantitative methylation of ABA was achieved through the dropwise addition of 
an ethereal solution of freshly prepared diazomethane (70 mg, 1.66 mmol) to a stirred 
solution of ABA (100 mg in 5 mL of ether) (Figure 3.2).  The reaction was allowed to react 
at ambient temperature for 30 min.  The ether and excess diazomethane was removed 
under nitrogen to afford white crystals.  
Four stock solutions of methylated ABA at various concentrations, were prepared 
to a final concentration of 0.09, 0.5, 0.7 and 1.1 µM.  The auto-pipettes were calibrated 
prior to use where both accuracy and precision were found to have an acceptable 
deviation of -0.8% and 2.7% respectively.  Injections of 0.1 - 5.0 µL were injected into the 
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gas chromatographer using a HP-5ms column (30 m, i.d. 0.25 mm) incubated at an initial 
oven temperature of 100 °C and heated to a final temperature of 300 °C at a rate of 
30 °C.min-1.  The elution of the methylated ABA was determined using selective ion 
monitoring set to 278.3 ± 1.0 m/z. This molecular ion was formed through chemical 
ionization using methane as the reactant gas which was administered at 2 mL.min-1.   All 
injections were conducted in triplicate and the mean and standard deviation calculated.   
 
ABA detection in isoprenoid rescued parasites 
3D7 was synchronized with 5% (wt/vol) D-Sorbitol (Sigma-Aldrich) and washed 
three times with RPMI. 5 µM FOS or 2 µM DOX was added. For FOS-treated groups, 2 
µM GGPP or 200 µM IPP were added at the start. After 24 hours, parasites were saponin 
lysed and washed 3 times with PBS in 4 ºC, then stored in -80 ºC. For DOX-treated 
groups, parasites were resynchronized after 48 hours and parasitemia was adjusted to 
2%. DOX was added in addition to 2 µM GGPP or 200 µM IPP. After 24 hours, these 
were lysed and stored in the same manner as the FOS-treated group. Analysis was done 
on an Agilent 7890B Triple Quadrupole (QQQ) GC/MS. 
Methylation and detection was done using similar methods as above with 
modification. Seven stock solutions of methylated ABA were prepared to a final 
concentration of 1000, 500, 250, 100, 50, 25, and 10 nM. Injections of 3.5 µL were injected 
into the gas chromatographer using a Zebron ZB-5HT Inferno column (30 m, i.d. 0.25 
mm) incubated at an initial oven temperature of 100 °C and heated to a final temperature 
of 325 °C at a rate of 20 °C.min-1.  The elution of the methylated ABA was determined 
using a scan range of 277-282 m/z. All injections were conducted in triplicate and the 
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mean and standard deviation calculated.  Analysis was done on an Agilent 7890A 
Quadrupole Time-of-Flight (Q-TOF) GC/MS. 
 
13C-IPP synthesis  
Preparation of 13C Wittig Reagent. A solution of 9.23g (0.035 mol) of 
triphenylphosphine was dissolved in 25 mL of anhydrous THF under argon gas in sealed 
a round bottom flask and shielded from light. While stirring, 5g (0.035 mole) of 13C methyl 
iodide was added dropwise with a syringe and allow to run overnight at room temperature. 
The resulting product was rinsed with THF and dried under vacuum with rotary evaporator 
yielding 14g (0.0346 mol) of 13C methyltriphenylphosphonium iodide as a solid white 
powder (99% yield). Product was verified using 1H and 13C NMR. 
1. Silyl Protection of 4-hydroxybutan-2-one. A solution of 6g (0.088 mole) of 
imidazole and 6.3g of tert-butyldimethylsilyl chloride (0.042 mol) dissolved in 15 mL 
anhydrous dimethylformamide was added to a 50 mL round bottom flask under argon gas 
and sealed with a rubber septum. Solution was stirred and 3 mL (0.035 mole) of 
hydroxybutan-2-one was added dropwise under argon using syringe. Reaction was 
allowed to run overnight at room temperature and quenched with deionized water. 
Product was purified with hexane/water partition in separatory funnel and organic layer 
was dried under vacuum with rotary evaporator yielding 7g (0.0345 mole) of silyl protected 
alcohol as a clear oil (99% yield). Product was verified using GC/MS (EI) and 1H NMR 
(Figure 3.2).  
2. Wittig Reaction (Introduction of the 13C label). A 500-mL three-necked round-
bottomed flask fitted with a reflux condenser, solid addition funnel, and rubber septum 
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was sealed, evacuated, and filled with argon gas. 150 mL of anhydrous THF was added 
followed by 20 mL n-butylithium (2.5 M in hexanes). While stirring, 10g of 13C 
methyltriphenylphosphonium iodide was added slowly to form the ylide. 5g of silyl 
protected alcohol was diluted in THF and added dropwise through a syringe. Reaction 
was refluxed overnight at 66 ºC (with argon balloon) and quenched with ammonium 
chloride solution. Reaction mixture was extracted with pentane and dried under vacuum 
before purification on a silica gel flash column yielding 3.7 g of TBS protected 13C 
isoprenol as a clear oil (75% yield). Product was verified using GC/MS (EI) and 1H and 
13C NMR. 
3. Deprotection of Silyl ether. A solution of 50 mL THF and 15 mL pyridine was 
prepared in a polypropylene container and 5 mL 48% aqueous HF was added. Solution 
was stirred and 3.5g of TBS protected 13C isoprenol was diluted in THF and added 
dropwise, vessel was capped and stirred overnight at room temperature. Reaction was 
neutralized with saturated NaHCO3 (aq) and reaction mixture was extracted with 
dichloromethane in separatory funnel. Organic layer was washed with 15% CuSO4 and 
then 3% HCl to remove pyridine. Product was dried under vacuum and then purified using 
silica gel flash column yielding 1.16g of 13C isoprenol as a clear oil (77% yield). Product 
was verified using GC/MS (EI) and 1H and 13C NMR. This was phosphorylated according 
to methods outlined in [204]. 
 
3H enzyme activity assay 
Plasmodium vivax geranylgeranyl pyrophosphate synthase (PvGGPPS) was 
donated by Raymond Hui of University of Toronto. [1-3H] IPP triammonium salt (60 
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Ci/mmol) was purchased from American Radiolabeled Chemicals Inc. (ARC 0377A). To 
test activity of enzyme, a modified protocol was utilized [205]. 10 µM IPP, 5 µM DMAPP 
and 10 nCi 3H-IPP were added to a cocktail buffer containing 100 mM TrisCl (pH 7.7), 4 
mM MgCl2, 2 mM TCEP and 5 mg/mL bovine serum albumin (BSA) for a total volume of 
100 µL. 100 µg/mL enzyme was added and the reaction was incubated in 37 ºC for an 
hour. A sample without enzyme was prepared as a negative control. The reaction was 
stopped with 200 µL MeOH/HCl (4:1) and incubated for an additional 10 minutes.  400 µL 
pentane was then added, vortexed and centrifuged at 3000 rpm for 5 minutes. 200 µL of 
the upper organic phase was collected and added to a 96-well plate. Scintillation fluid was 
added upon drying and this was analyzed on a TopCount Scintillation Counter for counts 
per minute. 
 
13C3-GGPP reaction and purification 
100 μM 13C-IPP and 50 μM DMAPP were incubated in cocktail buffer with 100 
μg/mL PvGGPPS overnight for 12 hours. This was then flash frozen in liquid nitrogen and 
stored in -80 ºC before liquid-chromatography mass spectroscopy (LC-MS) analysis on 
an Agilent 6230 LC/MS TOF. Solvent A was 20 mmol ammonium bicarbonate, water and 
0.1% triethylamine (TEA). Solvent B was 9:1 acetonitrile/water (ACN/H2O) and 0.1% TEA. 
Electrospray (ESI) was done in negative mode with a scan range of 371-471 m/z.  
Injection volume was 20 μL with a flow rate of 300 μL/min starting at 2% solvent B for 3 
minutes and increased to 99% over 7 minutes. Retention time of analyte was 8.7 minutes. 
Reaction without BSA was used for purification on a Shimadzu 10A with SEDEX 75 ELSD 
high performance liquid chromatography (HPLC) system. Solvent A was H2O and Solvent 
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B was ACN. 400 μL was injected at a flow rate of 1.2 mL/min starting at 15% and 
increased to 99% over 10 minutes. Retention time of analyte was 6.8 minutes. 
 
13C3-GGPP metabolic labelling of P. falciparum 
1 mL asynchronous 3D7 culture was incubated in 12-well plates at 2% parasitemia 
in 4% hematocrit. 10 μM FOS and 2 μM 13C3-GGPP were added in addition to 50 μM 
FLD, 500 μM sodium tungstate (STS), 500 μM sodium bisulfite (SBS), or 100 μM 
naproxen (NAP). A control with 0.1% DMSO and an untreated RBC sample were also 
prepared. After 24 hours, the parasites were saponin lysed, washed three times with PBS 
and stored in -80 ºC. These were later analyzed with on a Q-TOF GC-MS according to 
methods outlined above.  
 
Results 
ABA is detected in Plasmodium falciparum extracts 
We initially wanted to confirm that ABA is detectable in blood stage parasite 
extracts. Without knowing what stage biosynthesis would be at its highest, we started with 
an asynchronous W2 culture. Groups consisted of a DMSO control and 50 µM fluridone 
(FLD). Parasite extracts were first methylated in order to derivatize the carboxlylic acid (-
COOH) portion of ABA into its methyl ester due to –COOH being weakly detected on GC-
MS (Figure 3.3). This changes the expected mass-to- charge ratio (m/z) from 264 to 278 
m/z. Nanogram (ng) quantities were obtained with a three-fold reduction in FLD-treated 
parasites (Figure 3.4). The experiment was repeated using different antibiotics (Figure 
3.5). An untreated red blood cell (RBC) control was also analyzed. ABA was detected in 
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our control in larger quantities. There was a significant difference between control and 
drug treated groups. ABA content was 40-80 times more abundant in control than those 
exposed to drugs. ABA was not detected in RBCs. 
 
Synthesis of 13C-IPP  
In order to get GGPP with three 13C labels, it was first necessary to synthesize 13C-
IPP, the basic isoprene unit which would be used in reactions with unlabeled DMAPP. 
13C-isoprenol was synthesized using a Witting reaction (Figure 3.2). The alcohol group 
was exchanged for the pyrophosphate in order to yield our end product, 13C-IPP.  
 
Synthesis of 13C3-GGPP  
PvGGPPS was donated and stored in -80 ºC prior to reactions. An assay with 3H-
IPP was performed to verify activity of enzyme prior to reaction (Figure 3.6). The assay 
aims to test if enzyme will form an acid stable product. The rationale behind this comes 
from the fact that IPP is nonallylic and stable in acid due to the position of its double bond. 
HCl breaks down acid sensitive compounds to their alcohol derivatives which can then 
be solubilized in organic solvents such as pentane and hexane. Likewise GGPP is 
expected to form geranylgeraniol (GGol) after acid treatment. Counts per minute were 
detected in reaction mixture exposed to the enzyme. As expected, no counts were 
detected when there was no enzyme, representing a lack of radioactive product 
formation. 
After the enzyme was confirmed to be active we did a test run to confirm GGPP 
production. Initially when scaling up the reaction, the substrate concentrations used were 
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1M IPP and 0.5M DMAPP. GGPP was detected but the yield was far less than expected.  
This was solved by decreasing the substrate concentrations down to 100 µM 13C-IPP and 
50 µM DMAPP (Figure 3.7). We were able to successfully synthesized 13C3-GGPP and 
found extending the reaction time from initially 2 hours to 12 hours had a significant impact 
on yield produced. 
 
ABA production in GGPP and IPP rescued parasites 
Isoprenoid inhibition of P. falciparum results in parasite death as IPP is an essential 
metabolite for survival. A drug like fosmidomycin (FOS) which targets DOXP 
reductoisomerase  (DXR), an enzyme early in the isoprenoid biosynthetic pathway, 
results in rapid death that is most effective at the ring stages. Exposure to doxycycline 
(DOX) reveals a delayed death phenotype that is characterized by death in the second 
life cycle. This is due to DOX’s ability to interfere with apicoplast replication such that the 
daughter parasites do not have one and therefore are unable to produce IPP. 
Supplementation of exogenous IPP is enough to reverse this for both methods of 
isoprenoid inhibition [155]. GGPP can rescue FOS-treated parasites but only has 
moderate effectiveness with DOX (Chapter 3). We wanted to see if IPP or GGPP rescued 
parasites would produce ABA. Parasites were synchronized and treated with FOS or 
DOX. IPP and GGPP were given to parasites at the same time as FOS and processed 
24 hours later. DOX treated parasites were given IPP and GGPP 48 hours later. This was 
done to ensure that they did not have an apicoplast. They were lysed and stored after an 
additional 24 hours. Controls were taken at 0, 24 and 72 hours. This would allow us to 
see any differences between early form parasites (0H) and later forms (24, 72H). 
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Unfortunately analysis was impeded by breakdown of the QQQ GC/MS when we tried to 
analyze the samples. Q-TOF was not sensitive enough to accurately quantify ABA at the 
low concentrations produced. 
 
Metabolic labeling of P. falciparum with 13C3-GGPP 
We aimed to block endogenous isoprenoid production with FOS, which would then 
be supplemented with 13C-GGPP for incorporation into the carotenoid biosynthetic 
pathway and ABA. In addition to FLD, carotenoid inhibitors, NAP, SBS and STS were 
given to parasites in order to detect an accumulation of intermediates in preceding steps 
(Figure 3.1). These three have activity against steps following catabolism to xanthoxin, 
which has not been identified in Plasmodium. Unfortunately the QQQ GC/MS used to 
detect and quantify ABA in the above experiment went down prior to analysis. A modified 
protocol was developed for use on a Q-TOF but our samples fell below the limit of 
detection and therefore we cannot make any conclusions about the fate of 13C3-GGPP. 
 
Discussion 
By using [1-3H] GGPP as a metabolic label, Tonhosolo et al. biosynthesized 
carotenoids which only incorporated two labels into their 40-carbon backbone. In order 
for ABA to be made, this is catabolized first into the 15-carbon xanthoxin before 
rearrangement into abscisic aldehyde followed by ABA. During this catabolic step, the 
label would have been lost and therefore ABA and its preceding intermediates would have 
been undetectable. We aimed to circumvent this by taking a different approach involving 
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the use of GGPP with three labels of 13C. Our carotenoids would have incorporated six 
labels and two were expected to be retained and detectable in ABA. 
The first signs of ABA production in an Apicomplexan parasite was obtained from 
T. gondii [163]. We speculated whether it might also be found in Plasmodium. We 
detected ABA in blood stage lysates. This was reduced when exposed to FLD, suggesting 
that the parasites may have a mechanism for making ABA, which can be blocked with 
carotenoid inhibitors. FLD inhibits PDS, the same enzyme that NFZ targets. PDS has 
been identified in Plasmodium, so a decrease in a detectable carotenoid catabolite is 
consistent with NFZ [158]. Different antibiotics that target the apicoplast reduced ABA 
with or without FLD, although those may be secondary effects not specifically due to 
inhibiting ABA. CLI and CAM exposure results in a delayed death effect with no significant 
decrease in parasitemia during the first life cycle [206]. As such 24 hour treatment 
wouldn’t be long enough to remove the apicoplast, although some later forms that had 
ruptured and became rings, may have been effected. The decline might also be attributed 
to overall decrease in protein synthesis in the organelle. 
Unfortunately we were unable to look for ABA in the rescue experiments with 
labeled and unlabeled GGPP due to unforeseen breakdown of the QQQ GC/MS. This 
equipment has high sensitivity suitable for nanomolar detection. We tried to work up a 
protocol on a Q-TOF GC-MS but our samples fell below the limit of detection (Figure 3.8). 
In the first rescue experiment with unlabeled GGPP and IPP, ABA appeared to be 
detected in all groups. Data was not consistent as the FOS-treated groups had higher 
values than those with either isoprenoid. These results were not valid and will need to be 
repeated on a more reliable instrument with greater sensitivity. 
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In the experiment with 13C-GGPP rescue, we expected to see 13C-ABA in groups 
exposed to FOS and 13C-GGPP. A peak corresponding to unlabeled ABA was detected 
but the retention time was shifted compared to standard (Figure 3.8). A possible 
explanation for this could be attributed to the fact that asynchronous cultures were treated 
with FOS. FOS is most active against ring stages and not as effective against later forms 
at inhibiting the isoprenoid pathway and causing parasite death. A future consideration 
would be to modify the protocol to start with rings but again, a functional QQQ GC/MS 
would be necessary to analyze this. 
We have not been able to identify candidates for ABA synthesis enzymes. ABA-
response genes have been found in T.gondii and are conserved in Plasmodium as well 
[163]. ABA is made via a more direct pathway in fungi, that utilizes farnesyl pyrophosphate 
(FPP) as a precursor instead of carotenoids [171]. We don’t expect Plasmodium to utilize 
mechanism however as it is a byproduct of the mevalonate pathway which is absent in 
Apicomplexans.  
Abscisic acid has a global role as a signaling hormone involved in calcium (Ca2+) 
release via cyclic ADP-ribose activity. This is conserved across plants, humans, T. gondii, 
and sponges [163, 164, 166, 173]. If ABA is produced in Plasmodium, it may have similar 
functionality. We’ve established a role of exogenous ABA to dormant parasites (Chapter 
2) which differs from endogenous role in plants. 
Despite not being able to analyze the label experiments proposed, we cannot rule 
out that ABA is synthesized by P. falciparum. Our initial GC-MS data seems promising 
and evidence in the form of the carotenoid pathway as well as ABA production in T.gondii 
help support this. The use of our 13C-GGPP with three labels for metabolic labeling in 
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Plasmodium is novel and has not been reported in literature. We plan to proceed with this 
and expect the label to be incorporated into ABA to confirm the missing part of the 
pathway (Figure 3.9). This could have applications to potentially uncover metabolites not 
yet characterized in Plasmodium and other organisms. 
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Figure 3.1. ABA pathway in plants. ABA is synthesized in plants via the MEP pathway. 
It initially occurs in chloroplasts and then shuttled out to the cytosol for completion 
Isoprenoid and carotenoid production has been confirmed in P. falciparum but the final 
steps starting from the catabolized xanthoxin to ABA has not. Inhibitors are highlighted in 
red [207-210].  
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Figure 3.2. 13C-Isoprenol synthesis. A Witting reaction was used to incorporate 13C into 
isoprenol. This was later phosphorylated to yield a molecule of 13C-IPP. 
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Figure 3.3. Schematic of ABA methylation. (A) ABA standard is methylated with 
diazomethane which converts the carboxylic group into its methyl ester. This is achieved 
due to the weakly detected carboxylic group on GC. (B) The total ion chromatograph of 2 
and (C) the corresponding SIM mass spectrum   
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Figure 3.4. ABA is detectable in the blood stages of P. falciparum. ABA is detected 
in ng quantities in asynchronous cultures. This was reduced 3-fold when exposed to 
carotenoid inhibitor, FLD, for 24 hours. 
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Figure 3.5. Antibiotics reduce the levels of ABA detected. ABA was detected and 
quantified in lysed parasites. This is reduced when exposed to antibiotics that target the 
apicoplast as well as fluridone. CLI = clindamycin; CAM = chloramphenicol; MIR = 
mirincamycin; FLD = fluridone; RBC = red blood cell; Statistics were analyzed by one-
way ANOVA with Newman-Keuls multiple comparison test; p< 0.05  
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Figure 3.6. Enzyme assay schematic.  (A) Enzyme is incubated with substrates at 37 
ºC. HCl/MeoH is used to stop the reaction and the acid cleaves off the phosphate group 
from 3H-GGPP yielding its alcohol derivative, 3H-geranylgeraniol. This was partitioned 
with pentane and collected for counts representing radioactive product formed. (B) 
Counts per minute were obtained in presence of PvGGPPS. Bars represent ± SEM 
 
E= enzyme, S = substrate, P = product   
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Figure 3.7.  13C3-GGPP detection on LC-MS. 13C3-GGPP was detected on LC-MS. 
Retention time was 8.7 min and corresponding mass was 452.1802. 
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Figure 3.8. FOS + 13C3-GGPP sample compared to ABA standard. A broad peak was 
observed with a mass representing unlabeled ABA. There was a shift in retention time 
compared to standard. One potential explanation for unlabeled ABA is FOS was given to 
a mixed culture which had later forms that are less susceptible to the drug than rings. The 
Q-TOF is also not sensitive enough to accurately detect low quantities and samples fell 
below limit of detection  
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Figure 3.9. Proposed pathway for ABA biosynthesis in P. falciparum. 13C-IPP 
condenses with DMAPP to form 13C3-GGPP. This feeds into carotenoid biosynthesis and 
we expect the fate of two labels to be incorporated into ABA, abscisic aldehyde and 
xanthoxin. Stars represent 13C label.   
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Table 3.1. Carotenoid inhibitor IC50s against 3D7 
 
IC50s for several carotenoid inhibitors against 3D7. Target represents enzymes in plants 
that are inhibited. 
  
Inhibitor Abbreviation IC50 (µM) Target 
Clomazone CLZ 249.7 Doxp synthase 
Fluridone FLD 60.3 ± 3.04 Phytoene desaturase 
Isoxaflutole ISF 91.9 ± 29.17 4-hydroxyphenylpyruvate 
dioxygenase (HPPD) 
Naproxen NAP 99.6 ± 0.34 Lipoxygenases 
Nicotine NIC 46.6 ± 6.4 N/A 
Norflurazon NFZ 36.6  ± 23.3 Phytoene desaturase 
Sodium bisulfite SBS > 500 ABA aldeyhyde oxidase 
Sodium tungstate STS > 500 Xanthoxin dehydrogenase 
Sulcotrione SUL 128.9 ± 72.3 HPPD 
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Chapter 4 
Synthesis of 13C3 geranylgeranyl pyrophosphate with Plasmodium and 
human geranylgeranyl pyrophosphate synthase 
 
Abstract 
Plasmodium vivax geranylgeranyl pyrophosphate synthase was previously cloned 
and its crystal structure and activity was characterized. It was found to be able to catalyze 
production of geranylgeranyl pyrophosphate (GGPP) from 5, 10 and 15 carbon 
isoprenoids. We intended to use this to synthesize 13C3-GGPP with three labels in order 
to metabolically label carotenoid precursors and characterize the abscisic acid 
biosynthetic pathway. Outlined here is work done to optimize expression and purification 
of this enzyme. A human variant of the enzyme was also used to optimize efficient 
reaction conditions. 
 
Introduction 
Plasmodium vivax geranylgeranyl pyrophosphate synthase (PvGGPPS) belongs 
to a family of protein transferases that catalyzes the reaction of geranylgeranyl 
pyrophosphate GGPP using isopentyl pyrophosphate (IPP) and allylic primers such as 
dimethylallyl pyropsphophate (DMAPP), geranyl pyrophosphate (GPP) or farnesyl 
pyrophosphate (FPP) [205]. The enzyme appears to be bifunctional as it shares homology 
with human GGPPS but is more closely related to farnesyl pyrophosphate synthase 
(FPPS) [205]. Despite this, it is more effective at producing GGPP. N-alkyl 
99 
 
bisphosphonates, which inhibit GGPPS and FPPS, have potent activity against 
Plasmodium parasites highlighting the importance of their activity for parasite viability 
[211]. GGPP plays an important role as one of the main isoprenoids involved in 
posttranslational modification of proteins. GGPP covalently binds to GTPases in other 
systems to switch on different biochemical pathways [212]. Protein prenylation is 
essential in P. falciparum as inhibition decreases parasite growth. GGPP also forms the 
building blocks of carotenoid biosynthesis which has been established in P. falciparum 
[158]. More recently a P. falciparum enzyme, PfFPPS (PF3D7_1128400) has been 
cloned and characterized for its bifunctional activity in producing FPP and GGPP [213].  
In chapter 2, we established that GGPP can reverse the effects of fosmidomycin 
inhibition. We aimed to exploit this by using 13C3-GGPP to confirm ABA biosynthesis in 
P. falciparum. The initial goal to synthesize 13C3-GGPP involved using PvGGPPS to 
catalyze the reaction of 13C-isopentyl pyrophosphate (13C-IPP) and DMAPP. Challenges 
were faced that resulted in switching to HsGGPS1 for additional optimization of reaction 
conditions. Ultimately we ended up using PvGGPPS after conditions had been properly 
optimized and good yield was obtained. Here is work done to express, purify and optimize 
conditions of the enzyme. 
 
Materials and Methods 
Small-scale expression of Plasmodium vivax geranylgeranyl pyrophosphate 
(PvGGPPS) 
Plasmid containing PVX_092040 which encodes for P. vivax protein was donated 
by Raymond Hui of University of Toronto. This contains an N-terminal His6 tag and TEV 
cleavage site (MGSSHHHHHHSSGRENLYFQ*G). Expression was modified from [214]. 
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This was transformed with E. coli BL21-CodonPlus (DE3)-RIL competent cells (Agilent # 
230245). 2 µL of 1:10 XL1-Gold β-mercaptoethanol was added to 100 µL cells and kept 
on ice for 10 minutes. About 40 ng DNA was added to this mixture and incubated on ice 
for an additional 30 minutes. Cells were heat-pulsed in a 42 ºC water bath for 20 seconds 
and then placed on ice for 2 minutes before being transferred to a 5 mL chilled falcon 
tube. 500 µL preheated SOC media was added to the tube. This was incubated at 37 ºC 
and shaken for 1 hour. 50 µL was used to streak an agar plate containing Luria-Bertani 
(LB) with 34 µg/mL chloramphenicol (CAM) and 100 µg/mL ampicillin (AMP). This was 
left to incubate at 37 ºC overnight. One colony from the agar plate was chosen to inoculate 
3 mL LB media containing AMP and CAM and incubated overnight at 37 ºC.  The cultures 
were diluted 1:10 in 5mL LB media and shaken at 250 rpm at 37 ºC until OD600 reached 
0.80. At this point 1M isopropyl-β-d-thiogalactopyranoside (IPTG) was added and the 
cultures were moved to 22 ºC for 8 hours. 
Protein expression was verified by western blot. An aliquot was run on a 10% SDS-
PAGE gel and transferred to nitrocellulose.  This was blocked for 1 hour with 10% milk 
(in PBS-Tween 20) and incubated overnight at 4 ºC with mouse 6x-His tag antibody 
(Invitrogen, #37-2900). This was washed three times with PBS-Tween 20 and incubated 
with1:3000 dilution of peroxidase-conjugated AffiniPure Goat anti-mouse IgG conjugated 
antibody for 1 hour following 3x wash. ECL reagent (GE Healthcare) was added and thr 
blot was imaged on a Konica Minolta SRX-101A x-ray developer. 
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Large scale expression of PvGGPPS 
E. coli was grown overnight at 37 ºC in 100 mL LB media. On the following day, 
25 mL was added to 470 mL terrific broth (TB) media consisting of 90% TB medium and 
10% potassium phosphate buffer (0.17M KH2PO4 and 0.72M K2HPO4). 5 mL of trace 
elements [200 mM FeCl3.6H2O, 95 mM ZnSO4.7H2O, 19 mM MnCl2.4H2O, 3 mM 
CuSO4.5H20, 9.7 mM H3BO3, 2.7 mM CoCl2.6H2O, 10 mM Na2MoO4.2H2O, 5% HCl 
(12N)]  was added and this was shaken at 37 ºC until OD600 = 0.80. 1M IPTG was added 
and left to shake for 8 hours at 22 ºC. This was centrifuged and the supernatant removed. 
Pellet was resuspended in 20 mL binding buffer (500 mM NaCl, 5% glycerol, 50 mM 
HEPES, pH 7.5, 5mM imidazole) with protease inhibitor cocktail [100 mM benzamadine 
HCl, 1 mM phenylmethylsulfonyl fluoride (PMSF)] and frozen at -80 ºC. 
 
Purification of PvGGPPS 
Pellet was thawed at 4 ºC overnight on day prior to purification. 0.5% CHAPS, 200 
µg/mL lysozyme and 50 µg/mL DNAse were added to the suspension and mixed for 40 
minutes at 4 ºC. This was sonnicated three times on ice and centrifuged for 20 minutes 
at 15,300 rpm at 4 ºC. Binding buffer was equilibrated with Ni Sepharose 6 Fast Flow 
resin (GE Healthcare Life Sciences, # 17-5318-02) at room temperature. The suspension 
was separated from pellet and added to the resin which was mixed for 1 hour at room 
temperature. This was centrifuged and washed three times with wash buffer (500 mM 
NaCl, 5% glycerol, 50 mM HEPES, pH 7.5, 30mM imidazole). The resin was added to a 
column and eluted with elution buffer (500 mM NaCl, 5% glycerol, 50 mM HEPES, pH 
7.5, 250 mM imidazole) in 10 aliquots of 1 mL. 1M dithiothreitol (DTT) was added 
102 
 
immediately followed by 0.5 M ethylenediaminetetraacetic acid (EDTA), 15 minutes later. 
Concentration was obtained on a NanoDrop Spectrophotometer (ND-1000), and protein 
was evaluated on a 10% SDS-PAGE gel. Protein was stored in -20 ºC until use. 
 
Initial expression and purification  
The plasmid was initially transformed under a different protocol with the following 
modifications that differed from above in BL21 DE3 pLys E. coli and expressed in LB 
broth which was verified with western blot. Lysate was stored at -80 ºC with DNAse and 
lysozyme in solubilizing buffer (8M urea, 20 mM sodium phosphate, 10 mM imidazole, pH 
7.8) prior to purification. After equilibration with Ni-NTA resin (Qiagen, #1018244), this 
was washed with wash buffer (8M urea, 20 mM sodium phosphate, 10 mM imidazole, pH 
7.8). This was eluted on a column with elution buffer (8M urea, 350 mM imidazole, pH 
7.8).  Protein was evaluated with 10% SDS-PAGE gel. 
 
Enzyme activity assays 
Enzyme activity of PvGGPPS was initially tested with 14C-IPP based off a previous 
described protocol [205].  [1-14C] IPP triammonium salt (55 mCi/mmol) was purchased 
from American Radiolabeled Chemicals Inc. (ARC 0541) 100 µL reaction tubes were 
prepared containing 50 or 250 µg/mL PvGGPPS and buffer with final concentration of 50 
mM Tris, 2mM MgCl2, 1mM TCEP, 5 mg/mL bovine serum albumin). Substrates 10 µM 
IPP, 5 µM DMAPP, 5 µM FPP and 10 nCi 14C-IPP were added according to Table 4 and 
incubated at 37 ºC. After a set time, reactions were stopped with 200 µL HCl/MeOH (1:4) 
and incubated for an additional 10 minutes. 400 µL pentane was then added, vortexed 
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and centrifuged. 200 µL of the upper organic layer was collected for reading on a 
scintillation counter. Recombinant human GGPS1 (HsGGPS1) protein was ordered from 
Abcam (catalog # ab100959). Comparison reactions to HsGGPS1 were done in a similar 
manner using 10 nCi 3H-IPP with 1 and 10 µg/mL enzyme concentration.  
3H-geranylgeranyiol product was verified by thin layer chromatography (TLC). A 
30 minute reaction was set up with 250 µg/mL PvGGPPS. 450 µL pentane was added 
after HCl/MeOH and 350 µL was collected. 35 µL was then counted on a scintillation 
counter. The remaining liquid was dried down with nitrogen and 10 µL hexane was added. 
1 µL was spotted on a silica plate alongside farnesol (5 µg/mL) and geranylgeraniol (10 
µg/mL) standards. Mobile phase was ethyl acetate/toluene (1:3). The plate was sprayed 
with En3hance (Perkin Elmer) and placed in an autoradiograph cassette for three days 
before transferring to X-ray. 
A modified protocol  was performed with 100 µg/mL PvGGPS with 750 nmol IPP 
and 75 nmol DMAPP in 850 nmol potassium phosphate (K+) buffer (pH 7.0) and 85 nmol 
MgCl2 [215]. After incubation at 37 ºC for one hour, MeOH was added to make a final 
mixture of 10%. This was run through a Sep-Pak tC18 vac cartridge (Waters, #186004618) 
that had been prewashed with 100% MeOH followed by 10% MeOH. Drop through was 
collected, followed by wash with 10% MeOH. Product was eluted with 90% MeOH. After 
drying with a Speedvac, these were spotted on a silica plate to verify GGPP by TLC 
analysis. 
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GGPP synthesis and quantification  
GGPP was synthesized, analyzed and quantified according to methods outlined in 
Chapter 3. 
 
Results 
Enzyme expression and purification optimization 
The plasmid was originally expressed and purified under a different protocol which 
yielded insoluble protein that formed inclusion bodies. Expression was modified after 
using BL21-CodonPlus (DE3-RIL) E. coli for transformation. Our protein of interest was 
43 kDa (46 kDa with TEV cleavage site) and was detectable at around the 50 kDA mark.  
Lower weight fragments were detected, suggesting there may have been some slight 
degradation. E. coli from Lane 4 was chosen for further growth and expression as it 
exhibited the least amount of degradation (Figure 4.1A). Optimization conditions were 
performed as outlined in Figure 4.1B. Expression seemed to be slightly higher with TB 
media although a significant difference wasn’t observed between groups (Figure 4.1C). 
22 ºC, 1 mM IPTG for 8 hours was chosen as expression conditions. Enzyme was soluble 
and purified with Ni Sepharose 6 Fast Flow resin (Figure 4.2) 
 
Purified PvGGPPS is active and produces GGPP 
Enzyme activity was first verified using 3H-IPP in reactions with IPP and DMAPP 
or FPP (Figure 4.2A). Except where noted, all were run for 30 minutes. Increased counts 
per minute (CPM) were observed when time was extended. The highest CPM was in 
reaction without cold IPP. This was expected as all IPP used to make GGPP were 
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radioactive and not diluted with nonradioactive substrate. Using FPP as a substrate also 
yielded higher counts at 30 minutes. This is likely do to fast reaction because FPP 
contains 15 carbons. This requires only one isoprene unit to make GGPP, as opposed to 
DMAPP needing three. The kcat value with FPP is 0.8 s-1 vs 0.5 s-1 with DMAPP [205]. No 
CPM were obtained at time 0, and reactions with no enzyme or DMAPP. This was all 
expected and confirmed validity of the assay. Without an allylic primer, such as DMAPP 
or FPP, the enzyme cannot make GGPP. In order to verify that the product being 
synthesized is GGPP, TLC was run. After acid treatment to form 3H- GGol, this was 
spotted on TLC (Figure 4.3B). The sample matched standard and this radioactive product 
was visible on an autoradiograph.  
This reaction was done in K+ buffer and spotted on TLC, but was weakly detected 
(Figure 4.4). GGPP was undetectable when analyzing on LC-MS. We suspected that 
interference from the phosphates in the K+ buffer for the nonradioactive reaction may be 
causing interference. A comparison reaction was performed using 3H-IPP and 50 µg/mL 
enzyme for one hour in both types of buffers (Figure 4.5). The reactions were significantly 
different. All reactions to synthesize GGPP were conducted in Tris based buffer following 
these results. 
 
13C-GGPP synthesis with HsGGPS1 and PvGGPPS1 
Despite changing buffer conditions for nonradioactive reaction, GGPP remained 
undetectable when analyzing reaction mixtures on LC-MS. Human GGPPS (HsGGPS1) 
was purchased and used in reactions. A comparison reaction assay was set up using 1 
and 10 µg/mL of PvGGPS or HsGGPS1 (Figure 4.6). Counts were higher with HsGGPS1 
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under both conditions. GGPP reaction was conducted with 1 and 10 µg/mL HsGGPS1 
with IPP (1000 µM) and DMAPP (200 µM) for 2 hours. This was analyzed on LC-MS and 
we were able to detect low yields of GGPP. We were also able to detect 13C3-GGPP when 
13C-IPP (1000 µM) and DMAPP (333 µM) was used (Figure 4.7). LC-MS revealed a value 
of 452.1967 m/z compared to 449.1896 m/z for GGPP standard, representing a shift by 
the three 13Cs.  After reducing 13C-IPP concentration down to 100 µM and altering the 
ratio of DMAPP used as well as length of reaction we were able to increase yield (Figure 
4.8). 50 µg/mL HsGGPS1 with 13C-IPP (100 µM) and DMAPP (50 µM) for 12 hours was 
determined to be the best working conditions for the reaction (Figure 4.9). 
With working conditions optimized for HsGGPS1, we ran reactions with PvGGPS 
adjusting enzyme concentration and reaction time (Table 4.2). The most 13C3-GGPP 
seemed to be produced with 100 µg/mL HsGGPS1 for 6 hours. Surprisingly calculated 
concentration obtained were higher in PvGGPPS reactions than HsGGPS1 reactions. 
 
Discussion 
E. coli as expression vectors are useful for production of recombinant proteins. 
They are easily malleable to transformation with plasmids containing genes for protein of 
interest. Growth and expression conditions however vary greatly from protein to protein 
as well as the vector. Optimization requires finding the right set of conditions that will 
maximize yield and make purification simple. The original protocol that was used to 
express and purify the protein yielded insoluble material. The protein was detectable via 
western blot but would not properly elute in the buffers used. Switching from a phosphate 
based buffer to HEPES based buffer with slightly lower pH resulted in soluble protein that 
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was easily eluted. When optimizing conditions for efficient expression, thicker bands were 
observed with E. coli cultured in TB media. These were supplemented with trace elements 
which enhanced growth and improved expressions. There wasn’t however any significant 
difference observed when altering temperature or length of expression. There was 
sometimes fragmentation detected at the 64 and 37 kDa mark. This potentially may have 
been due to degradation and/or aggregation of protein. 
After verifying activity to synthesize GGPP with the radiolabeled IPP assays, eluted 
product was spotted on a TLC. We were able to detect faint band for GGPP but this was 
not consistent. Often unreactive IPP would be detected suggesting there was something 
wrong with our reaction. At first it seemed it may have been the K+ buffer used for the 
reaction. To verify this theory, a comparison assay was done with 3H-IPP and counts were 
higher with Tris buffer. Unfortunately that did not solve the problem as GGPP was 
undetectable in LC-MS as well as NMR (data not shown). Following these challenges, we 
switched to a human variant as Plasmodium specific enzyme was not needed for the 
reaction. 
We initially attempted to run the reaction with HsGGPS1, 1M IPP and 0.5M 
DMAPP. GGPP was detected but recovered yield was under 1% (data not shown). We 
learned this was due to potential substrate inhibition. Kavanaugh et al. reported that there 
is no substrate inhibition up to 100 µM of IPP [216]. After reducing both IPP and DMAPP 
to 100 and 50 µM, the recovered GGPP yield increased. This explained why the enzyme 
assays worked as those were done with 10 and 5 µM substrates, which were too low to 
cause any inhibition. We scaled up to increase GGPP yield, not realizing this had a 
negative effect on production.  
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While keeping the concentration of IPP at 100 µM, reactions were done with 
DMAPP at concentration ranges from 20, 33, 50 µM). The highest yield was obtained 
when they were in a 2:1 ratio (Figure 4.9). When this was scaled up to 2 mL and ran 
overnight for 12 hours, the concentration significantly increased. After good reaction 
conditions were determined with HsGGPS1, we tried to optimize GGPP production with 
PvGGPPS. The values were higher when compared with HsGGPS1 in the assays with 
radiolabeled IPP. The differences in substrates may affect efficiency of the enzymes with 
lower substrates yielding higher yield with HsGGPS1 as opposed to PvGGPPS. 
After reducing the substrate concentrations, the reaction was repeated and purified 
on LC-MS. Upon drying however, crystals formed with the product and the mass was 
larger than expected. We deduced that it was due to BSA (5 mg/mL) used in the buffer. 
GGPP was being bound to the albumin and was the reason why we were unable to purify 
it. The reaction was repeated again with PvGGPS, without BSA, and crystals did not form 
so we were able to purify product. There was potential product inhibition that was reduced 
by the presence of BSA and removing it led to lower yields of GGPP.  The 13C3-GGPP 
that was recovered was used in the experiments outlined in Chapter 3. 
GGPPS represent enzymes that synthesize important GGPP that is essential for 
protein prenylation, carotenoid biosynthesis and other terpenes across a large variety of 
living organisms. We previously showed that GGPP supplementation can reverse the 
effects of fosmidomycin inhibited isoprenoid biosynthesis in the erythrocytic stages of P. 
falciparum (Chapter 2), highlighting an important role it plays in parasites viability. 
Following PvGGPPS expression and purification, we were able to synthesize 13C3-GGPP. 
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This can be used in metabolic labeling of isoprenoid products to identify unknown 
metabolites and further elucidate incomplete biochemical pathways. 
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Figure 4.1. Expression optimization. (A) 4 separate colonies were selected from agar 
plate and expression as induced. E. coli from lane 4 was chosen for further expression 
due to least fragmentation in western blot. (B) PvGGPPS expression optimization is 
summarized. (B) SDS gel of whole lysate following IPTG. Expression conditions chosen 
were TB media, 22 ºC, 1 mM IPTG for 8 hours. * Lane 3 received 1.5 mM IPTG  
Lane
Length
IPTG
Temperature
Media
Insert PVX_090240
LB/TB
15
0.5 mM
8H
1
16H
2
1.0 mM
8H
3
16H
4
22
0.5 mM
8H
5
16H
6
1.0 mM
8H
7
16H
8
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  Protocol 1                 Protocol 2 
         
 
Figure 4.2. Purification of PvGGPPS. 46 kDA PvGGPS (with TEV cleavage site) was 
expressed and detected in E. coli induced with IPTG and purified using two methods. This 
is a comparison of 10% SDS gels of 2nd protocol versus 1st protocol which yielded 
insoluble protein. 
I = induced; UI = uninduced; BB = before binding; AB = after binding; E = elution   
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Figure 4.3. Confirmation of PvGGPPS activity using 14C-IPP. (A) Radioactive counts 
representing reaction product were obtained. This was increased in a time dependent 
manner. (B) In a separate reaction 3H-IPP was used. TLC and an autoradiograph were 
used to confirm that 3H-geranylgeraniol was the product that was created.  
F = farnesiol, S= sample, GG = geranylgeraniol 
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Figure 4.4. GGPP was detected via TLC. GGPP reaction product was eluted with 90% 
MeOH on a Sep-Pak C18 cartridge following small scale reaction. GGPP was visible in 
lane 3 compared to GGPP standard. Lanes 1 = drop through, 2 = wash, 3 = eluate,  
4 = GGPP standard (3 µg), 5 = Citr-P 
  
1       2        3        4        5 
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Figure 4.5. PvGGPPS is more active in Tris buffer. Reaction with 50 µg/mL PvGGPPS 
was conducted with 3H-IPP for 1 hour. Significantly more counts were obtained in Tris 
buffer vs K+ buffer. One-way ANOVA was performed for statistical significance. Bars 
represent ± SEM   
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Figure 4.6. HsGGPS1 is more active than PvGGPPS. Comparison of PvGGPPS 
activity to HsGGPS1 revealed that HsGGPS1 is more active. This is most pronounced 
when 10 µg/mL enzyme was used per reaction. Bars represent ± SEM 
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Figure 4.7 Substrate inhibition of HSGGPS1 led to reduced 13C3-GGPP production 
13C3-GGPP was detected but at very low quantity. This was due to substrate inhibition 
that was interfering with enzyme activity at high concentrations. Arrows represented 
contamination in column that was also present in blanks 
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Figure 4.8. 13C3-GGPP yield is increased with lower substrate concentration. More 
GGGPP was synthesized when the concentration of IPP:DMAPP were reduced from 
1000:500 µM to 100:50 µM. This reaction was done using 50 µg/Ml HsGGPS1 for 2 hours. 
Arrows represented contamination in column that was also present in blanks 
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Reaction 13C-IPP (µM) DMAPP (µM) Time (hour Yield (µM) 
A 100 20 2 0.9 
B 100 33 2 1.0 
C 100 50 2 1.6 
D 100 50 12 14.3 
 
 
Figure 4.9. HsGGPS1 reaction optimization. Decreasing the ratio of IPP:DMAPP from 
5:1 to 2:1 led to increased 13C3-GGPP in reactions. This was also enhanced by extending 
the time from 2 to 12 hours.  
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Table 4.1 : 14C-IPP PvGGPPS reactions   
Contents 1 2 3 4 5 6 7 
IPP + + + + + + + 
DMAPP + + + + + - - 
FPP - - - - - - + 
14C-IPP + + + + + + + 
PvGGPPS + + + - + + + 
Reactions 4 and 5 served as negative controls with no enzyme or DMAPP, respectively. 
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Average and SEM. from two independent runs  
Table 4.2 : Enzyme reaction optimization  
Reaction Enzyme Concentration 
(µg/mL) 
13C-IPP 
(µM) 
DMAPP 
(µM) 
Time 
(hours) 
Yield 
( µM) 
A PvGGPPS 10 100 50 3 6.71 ± 6.2 
B PvGGPPS 50 100 50 3 19.7 ± 11.8 
C PvGGPPS 100 100 50 3 30.64 ± 2.06 
D PvGGPPS 10 100 50 6 15.2 ± 15.6 
E PvGGPPS 50 100 50 6 27.2 ±  8.9 
F PvGGPPS 100 100 50 6 30.5 ± 7.5 
G PvGGPPS 10 100 50 12 18.4 ± 23.3 
H PvGGPPS 50 100 50 12 22.1 ± 17.5 
I PvGGPPS 100 100 50 12 10.5 ± 10.6 
J HsGPPS1 50 100 50 3 12.2 ± 1.9 
K HsGPPS1 50 100 50 6 15.5 ± 2.6 
L HsGPPS1 50 100 50 12 18.8 ± 2.0 
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Chapter 5 
Summary 
 
Despite tremendous efforts to eliminate malaria, it continues to pose a significant 
global threat. Artemisinin-based combination therapies have represented an effective 
form of treatment which is now threatened due to emerging resistance that echoes an all 
too familiar pattern of past antimalarials. A more comprehensive understanding behind 
the underlying mechanisms behind how parasites are able to tolerate drug pressure and 
develop resistance formation is essential. 
The concept of dormancy can partially offer some insight into what may promote 
the viability of resistant parasites. Most antimalarials gain their activity by interfering with 
essential metabolic processes and/or introducing toxins that are harmful. This is the case 
with chloroquine which interferes with breakdown of toxic heme as well as atovaquone 
which disrupts pyrimidine biosynthesis [73]. Growing parasites are susceptible to 
damage. By arresting growth and shutting down most metabolic activity, dormant forms 
are able to exist in the presence of drug and are effectively protected from the harmful 
effects that may otherwise kill them. Removal of drug exposure allows them to exit this 
state and resume their growth as detectable levels of parasitemia rises. 
In this study we explored the effects of the two primary dormancy regulating 
hormones of higher plant species for their effect on dormancy induced by a prominent 
antimalarial. While they share antagonist roles in plants, that didn’t appear to be the case 
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with P. falciparum. Parasites exhibited similar responses when exposed to both GA and 
ABA. Recovery was stimulated and we observed parasites exit dormancy earlier than 
non-treated groups. They occurred via an unknown mechanism and additional work will 
need to be conducted in order to elucidate how GA and ABA mediated recovery. Some 
potential theories could be the answers but further research could that. ABA’s role as a 
global Ca2+ signaler across a wide range of organisms, including T. gondii, might be 
conserved in Plasmodium. This may signal pathways and stimulate mechanisms that are 
used in the recovery process of dormant parasites. ABA has been able to influence mRNA 
expression and GA is theorized to activate enzymes that mediate the release from 
dormancy in seeds [122, 169, 217]. Any effect on expression of enzymes and 
upregulation of key genes involved in recrudescing might be identified by monitoring the 
response to the phytohormones. 
FLD is an effective inhibitor of carotenoid biosynthesis that reduces ABA in plants 
and releases seeds from dormancy. This has not been retained in Apicomplexan 
parasites as it induces formation of dormant bradyzoites in T. gondii and prolongs 
dormancy in P. falciparum. Exposure to it didn’t induce dormancy in P. falciparum but it 
had a negative effect on growth and progression through the life cycle was slow. If ABA 
is in fact being synthesized by dormant parasites and this is used in the recovery process, 
FLD’s block could help explain why exposure to it prevents recrudescence. 
Resistance often forms due to treatment incompliance. This is seen in patients that 
do not take antimalarials as recommended, especially if symptoms have subsided.  
Finding a mechanism to release dormancy is a potential way circumvent this form of drug 
evasion. By accelerating recrudescence, parasites become vulnerable and susceptible to 
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antimalarials more rapidly. This could be of special importance if the same phenotype is 
observed in liver stage dormancy of P. vivax hypnozoites which have limited antimalarials 
that are effective against them. Relapses could be prevented by “waking” those dormant 
forms up and hitting them with antimalarials that are effective against growing forms. 
We’ve known of the apicoplast’s importance for parasite survival but its role in 
dormancy has not been reported. It is responsible for biosynthesis of essential 
isoprenoids and IPP alone can cause recovery in parasites that have all apicoplast-
related metabolism shut down in parasites that do not have the organelle. There is 
skepticism in the science community in regards to dormancy but we show that parasites 
without an apicoplast fail to recover but this can be reversed if IPP is supplemented 8 
days after inducing dormancy. It is unknown whether IPP is directly needed to recrudesce 
or several of its byproducts are key to exiting dormancy. It is likely that no one metabolite 
is responsible and it may be a consorted effort between many. GA nor ABA were able to 
stimulate recovery alone, but neither are sufficient enough to reverse the effects of 
doxycycline and sustain parasite viability. 
In this study, we aimed to use 13C3-GGPP to characterize ABA as well as 
carotenoid catabolites leading to its biosynthesis. The data from the experiments 
unfortunately were not able to be properly analyzed due to the unexpected malfunction 
of vital equipment. Nonetheless, synthesis of this metabolic label is important as it may 
have broader utilization beyond the carotenoid pathways. We successfully showed 
biosynthesis of 13C-GGPP with three labels which may have significant applications 
beyond this project. Our focus was on one specific portion of a known pathway but there 
may be off products that could be labeled that we were not looking for. This novel 
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approach may be useful in further characterizing pathways and identifying isoprenoid 
products that have not been established in Plasmodium and other organisms. 
In summary we have established a role for phytohormones in dormancy induced 
in the erythrocytic stages of P. falciparum. The apicoplast and isoprenoids it produces are 
essential for recovery. These findings further expand our knowledge about how an 
evolutionary link to plant biology is relevant to Plasmodium and a survival mechanism 
that both undergo in early developmental stages. Dormancy contributes to antimalarial 
resistance and these findings might reveal insights into how that might be regulated 
and/or manipulated. Although ABA biosynthesis was not confirmed, there is strong 
evidence to suggest that parasites produce it and we cannot conclude that it does not. 
13C3-GGPP has successfully been synthesized from purified PvGGPPS and a method for 
detection of 13C-ABA has been established. Confirmation of biosynthesis would introduce 
new questions such as do parasites create it as a response to stress? Does endogenous 
ABA regulate dormancy? What role might it play in resistance development? These will 
be important to know going forward and future work will need to be conducted in order to 
answer them as well as validate ABA as an end product of carotenoid biosynthesis in P. 
falciparum. 
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Figure A.1. FLD supplementation over 2 life cycles. 50 uM FLD resulted in parasites 
that progressed through the blood stages and a slower rate than control 
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Figure A.2. ABA supplementation over 4 life cycles. ABA was supplemented to 3D7 
over 4 life cycles and relative luminescence units were obtained daily. ABA had no impact 
on growth although reduced numbers were observed with 500 µM after 168 hours. This 
was done with AB+ human plasma. 
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Figure A.3. GGPP Standard curve. This was the calibration curve done to calculate 
GGPP concentration obtained from reactions.  
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